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Abstract
Azetidine-2-carboxylic acid (Aze) is the four-member homologue of proline. Aze and
substituted Aze are constituents of natural and pharmacological products and biologically
active compounds. The preparation of substituted Aze analogues is, however, a challenge
for which few routes have been reported. In studying general rnethodology for the
preparation of Aze derivatives, we have now focused on developing new routes for the
synthesis of Aze analogues with substituents at the 3- and 4-position. These orthogonally
protected amino acid-Aze chimeras have been designed to serve as tools for studying the
influence of conformation on peptide activity.
In chapter 2, the synthesis of azetidine 2-carboxylic acid (Aze) analogs possessing various
heteroatomic side chains at the 3-position is presented and features modification of 1-PhF-
3-allyl-Aze tert-butyl ester (2S,3)-2.1 (PhF = 9-(9-phenylfluorenyl)). 3-Allyl-Aze 2.1 was
synthesized from a sequence commencing with regioselective allylation of a-tert-butyl f3-
methyl N-(PhF)aspartate 2.13, followed by selective w-carboxylate reduction, tosylation
and intramolecular N-alkylation. Removal of the PhF group and olefin reduction by
hydrogenation followed by Fmoc protection produced nor-Leucine-Aze chimera 2.2.
Regioselective olefin hydroboration of (2S,3S)-2.1 produced prirnary alcohol 2.23, which
was protected as a silyl ether, hydrogenated and N-protected to give 1-Fmoc-3-
hydroxypropyl-Aze 2.26. Enantiopure (2S,3S)-3 -(3 -azidopropyl)- 1 -fmoc-azetidine-2-
carboxylic acid tert-butyl ester 2.3 was prepared as a Lys-Aze chimera by activation of 3-
hydroxypropyl-Aze 2.26 as a methanesulfonate and dispiacement with sodium azide.
Moreover, orthogonally protected azetidine dicarboxylic acid 2.4 was synthesized as an Œ
arninoadipate-Aze chimera by oxidation of alcohol 2.26.
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Chapter 3, a study to deveïop new rnethodology for the preparation of 4-substituted Aze
analogues was performed. Three approaches were examined. In the first approach novel
2,4-disustituted azetidine-3-one 3.43 was synthesized for the ftrst tirne by employing an
intramolecular metal carbenoid N-H insertion of Œ-diazo t3-ketophosphonate 3.40 which
was prepared from L-serine as a curai educt. In the second approach, a SN2’ strategy has
been used to synthesize 4-vinyl Aze analogues. For example, diastereomeric mixture of 4-
propenyl N-(Phf)Aze 3.4$ was synthesized by the Homer-Wadsworth-Emrnons (HWE)
olefination of a-tert-butyl-N-(PhF)aspartate t3-aldehyde 3.42 with fi-keto phosphonate 3.44,
followed by reduction of the resulting c3-unsaturated ketone 3.45, activation of the
corresponding alcohol 3.46 as a tosylate 3.47 and intramolecular SN2’ reaction. In an
atternpt to synthesize 4-vinyl N-(PhF) Aze 3.59, pipecolate 3.58 was forrned instead of 4-
substituted azetidine 3.59 during the SN2’ reaction in the presence of DMAP.
Diastereorneric mixtures of 4-vinyl Aze 3.65 were produced in 11 steps from aspartic acid
by application of allylglycine methyl ester 3.63 in a cross-metathesis/ intramolecular SN2’
N-alkylation strategy. The novel 4-substituted Aze analogues offer potential to serve as
precursors for making azabicyclo[4.2.O] and [5.2.O]alkane amino acids, such as 3.11 and
3.13. Although an alternative approach failed to produce 4-substituted Aze by
intramolecular ring opening of an epoxide by nucleophilic attack of a fi-amine, new amino
epoxides 3.70 and 3.74 were synthesized for the first time from L-Asp as an inexpensive
chiral educt. These amino epoxides may serve as intermediates for synthesis of other
ftinctionalized compounds.
We have developed new syntheses of arnino acid analogues including enantiopure 3-
substituted azetidine-2-carboxylic acids 2.2, 2.3 and 2.4, for exploring structure-activity
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relationships of various biologically active peptides. Also, we have developed new
methodologies for synthesizing 4-substituted Aze analogues 3.43, 3.48, 3.65, which may
enable syntheses ofnovel azabicyclo[X.Y.O]alkane derivatives. In summary, this thesis has
provided new methodology for making azetidines to explore their conformational and
biological properties.
Key words: azetidine 2-carboxylic acid; azetidines; amino acid; chimera; heterocycle;
peptide synthesis
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$ommaire
L’acide 2-azétidine carboxylique (Aze) est un homologue à quatre chaînons de la proline.
Aze et Aze substitué sont des constituants de produits naturels et pharmacologiques ainsi
que de composés biologiquement actifs. La préparation des analogues d’Aze substitués est,
cependant, un défi pour lequel peu de voies de synthèse ont été reportées. En étudiant une
méthodologie générale pour la préparation des dérivés d’Aze, nous nous sommes
concentrés à développer de nouvelles voies de synthèse pour les analogues d’Aze
substitués en position 3 et 4. Ces chimères d’Aze ont été élaborées pour servir d’outil dans
l’étude de l’influence de la conformation dans l’activité des peptides.
Dans le chapitre 2, la synthèse d’analogues de l’acide 2-azétidine carboxylique (Aze)
possédant différents hétéroatomes sur les chaînes latérales à la position 3 est présentée en
plus de la modification de l’ester tert-butylique du 1-PhF-3-allyl-Aze (2S,3S)-2.1 (Phf = 9-
(9-phénylfluorényle)). Le 3-allyl Aze 2.1 a été synthétisé tout d’abord avec une allylation
régiosélective du diester Œ-tert-butylique r-méthylique de l’acide N-(PhF)aspartique 2.13,
suivie par une réduction sélective du w-carboxylate, tosylation et N-alkylation
intramoléculaire. Le clivage du groupement PhF et la réduction de l’oléfine par
hydrogénation suivis par une protection avec un groupement Fmoc ont produit la chimère
norleucine-Aze 2.2. Une hydroboration régiosélective de l’oléfine (2S,3S)-2.1 a produit
l’alcool primaire 2.23, qui après protection par un groupement éther de silyle,
hydrogénation et protection de l’amine a donné le 1-Fmoc-3-hydroxypropyle-Aze 2.26.
L’ ester tert-butylique énantiopur de l’acide (2S, 38)-3 -(3 -azidopropyle)- 1 -Fmoc-azétidine
2-carboxylique 2.3 a été préparé comme une chimère de la Lys-Aze par activation du 3-
hydroxypropyl-Aze 2.26 comme un méthanesulfonate et déplacement avec un azidure de
Vsodium. De plus, l’acide dicarboxylique 2.4 de l’azétidine protégée orthogonalement a été
synthétisé comme une chimère du Œ-aminoadipateAze par oxydation de l’alcool 2.26.
Dans le chapitre 3, une étude pour développer une nouvelle méthodologie pour la
préparation des analogues de l’Aze substitué en position 4 a été réalisée. Trois approches
ont été examinées. Dans une première approche, l’azétidine-3-one 2,4-disubstituée 3.43 a
été synthétisée pour la première fois en employant une insertion intramoléculaire d’un
carbénoïde métallique N-H du Œ-diazo 3-cétophosphonate 3.40 qui a été préparé à partir de
la L-sérine comme entité chirale. Dans une seconde approche, une stratégie SN2’ a été
utilisée pour la synthèse d’analogues 4-vinyle Aze. Par exemple, un mélange
diastéréomérique du 4-propényle N-(PhF)Aze 3.4$ a été synthétisé par oléfination
d’ Horner-Wadsworth-Emmons (HWE) du Œ-tert-butyl-N-(PhF)aspartate f3 -aldéhyde 3.42
avec le f3-cétophosphonate 3.44, suivie par une réduction de la cétone u,f3-insaturée
résultante 3.45, activation de l’alcool correspondant 3.46 comme un tosylate 3.47 et une
réaction intramoléculaire SN2’. Dans une tentative de synthèse du 4-vinyl N-(PhF) Aze
3.59, le pipécolate 3.58 a été formé au lieu de l’azétidine 4-substituée 3.59 durant la
réaction SN2’ en présence de DMAP. Un mélange diastéréornérique du 4-vinyle Aze 3.65 a
été produit en 11 étapes à partir de l’acide aspartique par application de l’ester méthylique
de l’allylglycine 3.63 dans une stratégie de métathèse croisée / N-alkylation
intramoléculaire SN2’. Ces nouveaux analogues de l’Aze substitué en position 4 peuvent
servir comme précurseurs dans la synthèse des acides aminés [4.2.0] et [5.2.0]
azabiycliques, tels que 3.11 et 3.13. Bien qu’une approche alternative pour former l’Aze 4-
substituée par ouverture intramoléculaire d’un époxyde par attaque nucléophile d’une f3-
amine ait échoué, de nouveaux amino époxydes 3.70 et 3.74 ont été synthétisés à partir du
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L-Asp. Ces amino époxydes peuvent servir d’intermédiaires dans la synthèse d’autres
composés fonctionnalisés.
Nous avons développé de nouvelles synthèses d’analogues d’acides aminés dont les acides
3-substitués azétidine-2-carboxyliques 2.2, 2.3, 2.4, pour explorer la relation structure-
activité de différents peptides biologiquernent actifs. Aussi, nous avons développé de
nouvelles stratégies pour synthétiser des analogues de l’Aze 4-substitués 3.43, 3.48, 3.65,
qui devraient être utiles dans la synthèse de nouveaux dérivés de 13-lactame
azabicyclique[X.Y.O] alcane.
Mots Clés: acide 2-azétidine carboxylique; azétidines; acides aminés; chimères;
hétérocycles; synthèse peptidique
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1. Peptide ami peptide mimicry
1.1.1 Peptides and proteins:
A peptide is a chain of amino acids covalently linked together by amide bonds. Longer
peptides (usually more than 50 residues) are called proteins. Interest in peptide science
lias been great due to their remarkable biological and structural properties. Table 1 lists
some representative short natural peptides and their biological properties.”2
Table 1 Examples ofbiologically active peptides.
Name No. of residues Biological property
Thyrotropin-releasing hormone 3 A hormone that controls the release of
(TRH) another hormone (thyrotrophin) in the body,
and also affects the central nervous system
Enkephalins 5 found in the brain, these peptides are
involved in the control of pain sensations.
Phalloin 7 A poisonous bicyclic peptide, found in the
Deathcap toadstool
Angiotensin II $ This peptide is a hypertensive agent used by
the human body to increase blood pressure.
Oxytocin 9 A hormonal cyclic nonapeptide which,
among other things, induces labour in
pregnancy
Vasopressin 9 A cyclic peptide antidiuretic hormone that
induces contraction ofsmooth musctes.
Gramicidin S 10 A cyclic decapeptide antibiotic
Somatostatin 14 A cyclic peptide hormone that inhibits the
secretion of growth hormone, insulin and
glucagon.
Peptides exhibit nurnerous activities in human physiology as neurotransmitters,
neurornodulators, honTiones, antibiotics, growth factors, cytokines, and antigens. They
influence essentialiy ail vital physiological processes via inter- and intracellular
communication, and signal transduction mediated through various classes of receptors.3’4
An important goal of peptide research has been to elucidate the relationship between the
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three-dirnensional (3D) structure and biological activity of a peptide. Sucli information is
usefril for developing therapeutic agents to control or intervene in disease states involving
peptide receptors.
1.1.2 Structure of peptides:
Peptides share a common structure featuring a polyamide backbone and side chains
linked to the ci-carbons of the amino acid residues. The primary structure of a peptide
consists ofthe linear amino acid sequence (figure 1.1).
The secondary structure of a peptide describes local conformations such as ci helices and
f3 strands. The formation of secondary structure in a polypeptide chain is usually
contingent upon the primary structure and can be affected signfficantly by its
environment. Secondary structure elements typically arrange thernselves in motifs that
give rise to higher ordered structures by the close packing of side chains from adjacent ci
helices or f3 strands or inter-residue H-bonds (Figure 1.1).
Tertiary structure refers to the complete three-dirnensional structure of a given protein;
the spatial relationship of different secondary structures to one another within a
polypeptide chain and the fold of these secondary structures into a three-dirnensional
forrn. The interactions of different dornains are governed by several forces such as
hydrogen bonding, hydrophobic interactions, electrostatic interactions and van der Waals
forces.
Many proteins contain two or more different polypeptide chains that are held in
association by the sarne non-covalent interactions that stabilize the tertiary structures of
proteins. Proteins with multiple polypeptide chains are terrned oligomeric proteins. The
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structure formed by monorner-monorner interaction in an oligorneric protein is known as
quaternary structure.
Prinldry strucluic
Tertiary struGure
Figure 1.1: Schernatic illustration of the various structural forrns characteristic of
proteins. The primary structure is determined by the linear sequence of amino acids. The
secondary structure consists in chain segments that may have a-helical or f3-sheet
structure. The entire amino acid chain that forms the protein consists of connected
segments of secondary structure. These corne together to form the tertiary structure of the
protein.5
Set)ndary strci turcs
Chapter 1 5
1.1.3 The drawbacks of the use ofpeptides:
For peptide-based drug design, there are several major considerations that can limit the
clinical application of peptides such as: (i) rapid degradation by many specific or
nonspecific peptidases under physiological conditions; (ii) conforrnational flexibility
which allows a peptide to bind to more than one receptor or receptor subtype leading to
undesirable side effects; (iii) poor absorption and transportation because of their high
molecular mass and the lack of specific delivery systems, especially for peptides which
require passage across the blood-brain-barrier (BBB) to act in the central nervous system
(CNS).6°
1.1.4 Peptide mÏmicry and its ïmportance:
A peptide mimic refers to a molecule resembling a peptide, which can act like the peptide
as a ligand of a biological receptor or inhibit the effect of the natural peptide at its
receptor. Peptide-based enzyme inhibitors may also be considered peptide mimics. From
a medicinal chemistry point of view, peptide mirnics replicate the topology of the
peptide; however, they lack aspects of the peptide structure that may be drawbacks to the
use of the peptide as a dnig. In peptide rnimics, the peptide backbone and side chain
conformations may be constrained to allow a better interaction with the enzyme or
receptor protein to whici the peptide binds.6’ ‘, ‘°
1.1.5 The importance of peptidomïmetics in drugs:
The use of peptidomirnetics to overcorne the limitations inherent in the physical
ciaracteristics of peptides lias becorne an important strategy for improving the
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therapeutic potential of peptides. As one of the major efforts in organic chernistry, a
variety of molecules have been designed to mimic the secondary structures of peptides,
such as a-helices, f3-turns, and f3-strands. To explore structure-activity relationships
tSAR) of bioactive peptides, a number of strategies have been developed that feature
incorporation of conformationally constrained arnino acids, modification of the peptide
backbone by amide bond isosteres, cyclizations, attachment of pharrnacophores to a
template or scaffold, and the syntheses ofnon-peptide analogues.7’10 Peptidomimetics are
desired which exhibit the sarne biological effects as natural peptides, and at the sarne
time, are more metabolically stable. Peptidomimetics can possess favourable attributes
for drug development including, a conformationally restrained structure that may
minimize binding to non-target receptors and enhance activity at the desired receptor, and
irnproved transport properties through cellular membranes. Certain peptide mimics, such
as amide isosteres,8 retro-inverso peptides,” cyclic peptides’2 and non
peptidomirnetics’3, have exhibited a reduced rate of degradation compared to native
peptides. Peptidomirnetics with improved pharmacokinetic profiles may also be designed
with molecular frameworks that direct the position ofthe pharrnacophores.6’ 14, 15
1.1.6 Different approaclies for peptide mimicry:
There are several different approaches for peptide mirnicry:
1) Backbone N-alkylation facilitates cis-trans amide bond isomerization and changes the
conformational space available to the p, ii and y dihedral angles (Figure 1.2). N
Aikylation eliminates the hydrogen bonding capability of the amide bond. N-Methylated
amino acids have been incorporated into bioactive analogues of the opioid peptides,’6
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34) segment of parathyroid hormone (PTH), several analogues of hPTH(1-1 1) were
synthesized (Figure 1.3). The substitution ofthe C0,0-dialkyiated amino acid residue Ac5c
in hPTH(1-l Ï) at position 1 resulted in a potent analogue with biological activity 3500-
fold higher than that of native PTH(1-Ï 1) and 15-fold weaker than that of the native
sequence hPTH(1-34). 26
(CH2) S-V-S-E-I-Q-L-M-H-Q-R-N H2
h PTH ( 1-11)-N H2
H2N CO2H
Figure 1.3: a-Arninocycloalkane carboxylic acid (Acn+3c)
3) D-Amino acid substitutions can favour formation of f3-tum structures. Replacement of
sorne or even ail L-amino acids with their corresponding D-amino acids in a peptide
sequence confers resistance to proteolytic degradation. Another important advantage for
peptide drug developrnent is that D-arnino acid analogues have been found to be
significantly less immunogenic than their L-amino acid counterparts.27 D-Amino acid
residues may stabilize a reverse f3-turn (hairpin) structure, as weli as increase potency,
affinity and activity due to the importance of f3-turn conformations for biologicai
activity.28
4) Peptide amide bond isosteres may restrain the u-dihedral angle to values O ° or 1800, or
allow greater freedom for rotation about this bond (Figure 1.4).
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HR
\ N\IJl
Peptide amide
H
Ketomethylene isosteres
X=Y= H or F
X=H,Y=OH
HR
\.NjJ)
Thioamide isostere
HR
\Njj)
Trans-oletin isosteres
X= H, F
H°
N\3
Azapeptide isostere
Ethylene isosteres
X=H,OH
H° R
cN\
ester isostere
Figure 1.4: Common amide bond isosteres8
For example, it is possible to elirninate both a backbone H-bond acceptor (C=O) and a
donor (N-H) by replacing the amide ftmctionality with an E-alkene moiety (Figure 1.5).
1
1/
R’
Figure 1.5: The backbone amide-to-E-olefin mutation eliminates both a H-bond acceptor
(C=O) and a donor (N-H).
The Phe-Phe E-olefin dipeptide isostere (Fig. 1.6) was incorporated into the 40 residue
Alzheirner’s amyloid peptide, referred to as Af3(1-40), in place of phenylalanines 19 and
20 utilizing a Boc/benzyl solid phase strategy, to examine the role of intermolecular H
bonding in the process of amyloidogenesis, that may cause Alzheimer’s disease. This
amide-to-E-alkene backbone mutation precludes arnyÏoid formation, but flot spherical
Methylene isosteres
X= S, Sf0), O
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aggregate formation, providing insight into the structural requirements of
amyloidogenesis.29
BocH N R
Ph
R= H, Me
Figure 1.6: Phe-Phe E-olefin dipeptide isostere
5) Cyclic arnino acids, suci as proline, 30,31 can lower the energy differences between the
cis and trans-arnide isorners and bias global restrictions of the conformation of a
peptide’s p and xi dihedral angles towards forming f3- or y-turns. Proline is often found at
the end of an Œ helix or in turns or loops. Unlike other arnino acids which exist almost
exclusiveÏy in the trans-amide form in polypeptides, proline can exist in the amide cis
conformation in peptides.32 litroducing pipecolic acid, called homoproline, instead of
proline into peptides is reported to introduce significant changes in biological activity and
has lead to interesting model compounds for studies on peptide conformation.33
Derivatives of pipecolic acid have also found a role as f3-turn rnimics34 as well as
precursors for natural product synthesis35 and rigid analogues of prolyl amide bonds in
peptides 36
6) Dehydroamino acids (Figure 1.7) can restrict the x dihedral angle to value of 00 (Z) or
180°(E). For example, a,f3-dehydrophenylalanine (APhe) has been used as a
conformationally restricted residue in the design of polypeptide helices. Dehydroamino
acids generally favor the formation of f3 or y-turns when placed in the (i+2) position of
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the putative turn sequence. In addition, sequential placement of APhe in a peptide induces
repeated [3-tums, that form a 310 helix-like structure (Figure
R+2
R1÷1 N
HN0 HNyRi+3
R) O
Figure 1.7: Dehydroarnino acid
7) f3-Alkylation bas been used to constrain the dihedral angle, and may also effect
backbone conformation. Introduction of methyl groups at the 3-position of Phe and
related aryl alanines lias been used to orient the arornatic ring. Additional alkyl groups
usually enhance the lipophilicity of the peptide analogue, and can thus help in crossing
the blood-brain barrier. Figure 1.8 represents structures of some novel arnino acids that
are constrained in x space.38 For example, the constrained tyrosine derivative, (2S,3S)-
2’,6’-dimethyl f3-rnethyltyrosine39 [(2S,3S)-TMT] (Figure 1.8 b) was synthesized and
incorporated into cyclic analogs of [D-Pen2,D-Pen5]enkephalin (DPDPE) (s’). Because of
the methyl substitution in the tyrosine derivative (Figure 1.8 b), rotation about the Xi and
torsion angles was restricted about the C-C bond. This tyrosine analogue has been
used in the study of the role of side chain dynarnics in peptide-receptor interactions and
protein functions.
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H
°N°
H
CH3 OH3 O
b
Figure 1 .8: a: Eiythro (28,3]?) f3-methyltryptophan40; b: (2R,35)-2’,6-dimethyl 13-
rnethyltyrosine39
In surnmary, incorporation of peptidomimetics into peptides can offer significant
advantages for drug developrnent. These benefits include increased bioavailability, better
transport through cellular membranes, decreased rates of excretion, increased selectivity
and decreased hydrolysis by peptidases. A tremendous variety of constrained amino acids
have been developed to rigidify particular amino acids and peptide sequences. Control of
backbone and side chain conformation by way of steric and electronic factors can be
implemented through modifications of the peptide backbone. Mirnetics are usually
designed based on analogy to the native peptide structure, then optimized to give the best
possible phamiacokinetic properties.
1.2 Cyclic amino acid chimeras
1.2.1 Proline and pipecolic acids as higher homologues of azetidine-2-carboxylic
acid
As mentioned, cyclic amino acids, such as proline and its higher homologue pipecolic
acid, are ofien used as conformationally constrained amino acids in peptide mimicry to
study conformation activity relationships in peptides.44 These amino acids increase
conformational freedom and favour turn geometry. 13-Substituted prolines and pipecolates
have been also been designed to serve as amino acid chimeras on which the ftmctional
H2N 002H
a
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groups of the amino acid side-chain are cornbined with the conformational rigidity of the
cyclic amino acid residue. Several chimeras based on proline bodies have becn used to
study the relationship between the side-chain geometry and the bioactivity in different
peptides.45’46’32 For example, proline-amino acid chimeras have been used in place of
namral amino acids in peptide-based enzyme inhibitors47 and in peptide ligands of G
protein coupled receptors (GPCRs). In the latter case, tyrosine was replaced with either
trans-3 -(4’-hydroxyphenyl)proline (t-Hpp) or cis-3 -(4’-hydroxyphenyl)prol inc (c-Hpp) in
6 opioid receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH and displayed 6
receptor binding affinity sirnilar to the parent TyrL —containing peptide (Figure 1 •9)•4$
-Substituted pipecolic acids have similarly been synthesized to serve as arnino acid
chimeras. for example, 3-substituted Pipecolic acid 1.2 was introduced into the potent
and sst5 subtype selective sornatostatin mirnetic 1.1 t1C50 = 87 nM). The resulting analog
1.3 tIC50 = 41 nM) exhibited 2-fold and 25-fold binding enhancement against the
sornatostatin receptor subtypes sst5 and sst4, relative to lead compound 1.1, respectively
49(Figure 1.9).
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TBDPSO”\1
QCO2H
Fmoc
R2CO2R1
R1= H, t-Bu
R2 t-Bu, i-Pr, n-Pr,
Me, Ph, 2-pyridyl
rigid analogues of prolyl amid
bonds in peptide.
/ \ NH
Second generation constrained
mimetic 1.3, 1050=41 nM
and pipecolate analogues.
1.3 Azetidine-2-carboxylic acids (Aze) anti their applications
1.3.1 Applications of azetïdine 2-carboxylïc acïd:
L-Azetidine-2-carboxylic acid (Aze) is a four member cyclic amino acid discovered by
Fowden5° and Vitanen51 in Convaltaria majatis and Poïgonatum offocinale, two members
ofthe Litiaceae family. Commercially available and isolated from hydrolysates ofnatural
plants,52 L-azetidine-2-carboxylic acid occurs in high concentrations in a variety of
species.
L-Aze exhibits growth inhibitory effects in many biological systems.54 L-Aze, as
constrained arnino acid, lias also found applications for the modification of peptide
conformation.556° L-Aze bas also been applied in synthesis as an additive for asymmetric
Aze, n= O
Pro, n= 1
Pip, n= 2
H2
cia-Pro-lys chimera
P1, P2: orthogonal
protecting groups
CH3
Pro-Val chimera
CO2H
R= Amino acid aide chain
Aze-Xaa chimeras n O
Pro-Xaa chimeras n= 1
Pip- Xaa chimeras n= 2
L-c-HppL-t-Hpp
sst5 selective turn mimetic, 11 1.2, 3-substituted
1055= 87 nM pipecolic acid
Figure 1.9: Structures of representative proline
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reduction of ketones,61 Michael additions,62 cyclopropanations,63 and the Diels-Alder
reaction.64
Some substituted Aze analogs are part of natural and phannacologically interesting
products such as medicanine,65 nicotianarnine,66 mugineic acid,67 and red-mold rice
fermentation products, some of which seem to be involved in ii-on transport processes of
certain plants.68 L-Aze derivatives have served as active pharmaceutical ingredients, in
for example, the non-opioid analgesic agent ABT-594(R) 69 and the thrornbin inhibitor
melagatran (Figure 1 .1 O).°
CO2H
N
H
L-azetidine-2-carboxylic acid (L-Aze)
CO2H CO2H CO2H HN
NNOH O
mugin&c acid HN H N R2
CO2H CO2H CO2H
NNNH2
O OR
nicotianamine
ABT-594(R) Thrombin inhibitor melagatran
Figure 1.10: L-Aze and examples of naturally and pharmaceutically important L
azetidine-2-carboxylic acid derivatives.
R= R= H: Melalagatran
REt, R= OH: Exenta
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1.3.2 Synthesis of azetidine 2-caboxylic acïds:
Cyclic a-amino acids have been the subject of considerable research in the last decade
because ofthe physiological activities associated with these derivatives.41’71’72 Although a
number of syntheses of cyclic arnino acids such as proline and pipecolic acid have been
developed, fewer rnethods are available for making azetidine-2-carboxylic acid
derivatives.
1.3.2.1 Synthesis of DL- and D-Aze starting from 2-bromo or 2-chloro-4-
aminobutanoic acid:
Racernic and enantiomerically enriched Aze have been synthesized respectively from y
aminobutyric acid 1.4 and L-a,y-diarninobutyric acid 1.6. Brornination of arnino acid 1.4
in the presence of red phosphorous gave a-brorno derivative 1.5. Ring annulations were
effected using 0.5 N barium hydroxide in H20 to yield (+)-Aze and opticalÏy active (+)-
Aze (Scherne 1.1).
H Br
H2NCO2H r2 H2NCO2H
1.4 1.5 Br
CO2H
Ba(OH)2
H20, heat
racemic-Aze
CIH3N —CO2H AgNO2 e e
I - CIH3N—CO2H
NH3CI z
o e ci
1.6
CO2H
Baf OH)2 E1
H20, heat
D-Aze
Scherne 1.1: Synthesis of (±) and (+)-Aze
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In addition, racemic Aze was also prepared from Œ-brorno- ‘y-arnino acid 1.10 using Z
pyrrolidinone 1.7 as a starting material.
Et( dimethyl sulfate NBS
N
OR / OR
N
1.7 1.8, 1.9,
R= CH3, C2H5 R= CH3, C2H5
HCI NH2CH2CH2CHCO2H Ba(OH)
1.10
racemicAze
Scheme 1.2: Synthesis of(±) Aze from 2-pyrrolidinone 1.7.
1.3.2.2 Syntliesïs ofAze starting from 7-butyrolactone:
The synthesis ofthe (+)-Aze was achieved from y-butyrolactone by a route featuring bis
aikylation of a given amine (Scheme 1.3). 75,76
1) (Ph)2CHNH2
1) Et2, P BtyCO2CH2Ph CH3ON, reflux
if 2) PhCH2OH Et 2) HCI, Et20
O HCI 1.11 3) Et3N, 0H013
CO2CH2Ph H2, 5% Pd,
CO2H
N\ CH3OH L_J\
CH(Ph)2 H
racemic Aze
1.12
Scherne 1.3: Synthesis of(±)Aze.
Enantiomerically enriched D- and L-Aze lias been obtained by resolution (Scheme
First, the DL-arnino acid was converted to its N-carbobenzyloxy derivative 1.13.
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Treatrnent with L-tyrosine hydrazide in MeOH yielded diastereorneric saits, which
exhibited different solubilities in methanol. 77,78
HC1
L-sait L-Aze
/ (soluble)CO2H L-Tytosine ‘‘2,
beyioformate
SOPh
__
racemicAze Q HC1
113 “ D-sait D-Aze(insoluble) H2Pd/C
Scherne 1.4: Resolution ofDL-Aze.
Enzyrnatic resoution of DL-N-substituted Aze has also been achieved using Candida
antarctica (Scherne 1.5), which produced carboxamide 1.16 from S-ester 1.14 using
ammonia as the nucleophule. R-Ester 1.15 did flot react under these conditions.79
CO2Me CO2Me CO2NH2
Candida antarctica t-i” +
‘R NH3, sat. t-BuOH, 35°C ‘R R
114 1.15 1.16
R 1.15 1.16
benzyi 99%ee 80%ee
p-methoxybenzyl 99%ee 84%ee
aiiyi 99%ee
benzhydryi 97%ee
Scherne 1.5: Enzyrnatic resolution ofN-substituted Aze.
1.3.2.3 Synthesis of L-Aze starting from (S)-N-toluenesulfonyl-homoserine lactone:
Enantiopure L-Aze was synthesized without resolution from N-toluenesulfonyl-L
methionine 1.17, which was readily converted to N-toluenesulfonyl-Iactone 1.19.
Treatment of L-hornoserine lactone 1.19 with hydrogen brornide, followed by cyclization
of 1.1$ with sodium hydride provided N-toluenesulfonyl-L-Aze 1.18. The
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toluensulfonamide was rernoved using sodium in liquid ammonia to give L-Aze in 62%
overali yield (Scheme 1.6). 80,81
HO2CS CH3I HO2CSH heatOH3
-
2 PH=6-7
HTs NHTs FHTs
1.17 1.18 1.19
HBr, EtOH EtO2C Bt NaH, DMF CO2H Na CO2H
60-70°C tIHTs H20 Liq. NH3 LH
Ts
1.20 1.21
Scheme 1.6: Synthesis of L-Aze from homoserine lactone 1.19.
1.3.2.4 Asymmetric synthesïs of (+)- and (-)-Aze from c.t-methylbenzyl amine as the
source of chirality:
Construction ofthe azetidine ring bas been achieved using an intramolecular aikylation of
a linear substrate derived from Œ-methyl benzyi amine as chirai aduct.82 a-Methylbenzyi
amine 1.22 was subjected to two consecutive aikylations with brornoethanol and
bromoacetonitrile to afford the tertiary amino alcohol 1.23. Chloride 1.24 was prepared
by reaction of aicohol 1.23 with thionyl chloride in dichioromethane. A 1:1 mixture of
diastereoisomers (S,S)- and (S,R)-1.25 were synthesized by intramolecular alkyation with
potassium tert-butoxide in THF. The diastereoisomers were separated by column
chromatography. Respective hydrolysis of nitriles 1.25 with concentrated hydrochioric
acid, foiiowed by hydrogenolysis ofthe HC1 sait gave the desired (-)- and (+)-azetidine 2-
carboxyiic acids (Scheme 1.7).
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1.35% HCI
2. H2,Pd/C,
MeOH (-)-Aze
X
t-BuOK,
NH2 1) alkylations ON
Ph’ 2) S00I2 NH—
I 1.35/oHOI
2. H2,Pd/O,
1.22 MeOH f+)-Aze
1.23, X= OH
1.24, X= 01
1.25, (S,R)
Scherne 1.7: Synthesis of (+)-Aze and (-)-Aze by intrarnolecular aikylation.
Employing benzyl a-bromo acetate, instead of brorno acetonitrile in the alkylation step,
gave a similarly unselective sequence, which provided Aze in similar overail yields.
In summary, prior syntheses of Aze have been reported; however, few provide a
satisfactory route to either enantiomer in practical quantities. Asyrnmetric syntheses have
required chernical and enzyrnatic resolution as well as the use of a chiral auxiliary. In
light of the importance of Aze and substituted Aze as constituents of biologically active
compounds, the development of new methodologies for synthesizing Aze analogues
remains an important field ofresearch.
1.4 Substituted azetidine-2-carboxylic acids
Introduction:
During our research on the effect of azacycloalkane amino acids on peptide
conformation, we became interested in employing f3 and ‘y substituted Aze analogues for
studying secondary structure. A search of the literature revealed that there are few
methods for selective and stereocontrolled introduction of aikyl substituents on the Aze
Ph
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ring carbons. In spite of cuiTent interest in the synthesis and chernistry of azetidine 2-
carboxylic acids, there are only a few reports on the synthesis of 3- and 4-substituted Aze
analogues.
1.4.1 3-Substituted azetidïne 2-carboxylic acids:
As mentioned, there are few general rnethods for the synthesis of substituted Aze
analogues. Several representative examples are presented below which deliver 3-
substituted Aze analogs in enantiopure forrn.
1.4.1.1 Synthesïs of Phe-Aze, Nal-Aze, Leu-Aze chïmeras:
Hanessian et aï. used Oppolzer’s sultam methodology for the preparation of enantiopure
3-substituted L-Aze analogs.83 The carnphor sultam derivative of glyoxalic acid O-benzyl
oxirne 1.26 on treatrnent with allylic halides and zinc dust was converted to allyl glycine
1.27. Hydrolysis of the curai auxiliary, esterification and N-protection produced N
benzyloxy tert-butyl amino esters 1.28. Oxidation of the olefin followed by reduction of
resulting aldehyde and mesylation provided the corresponding mesylate 1.29.
Hydrogenolysis followed by cyciization in the presence of NaHCO3 gave L-Aze methyl
esters 1.30 b-d as mesylate saits. Hydrolysis ofthe ester with 3N HC1 and purification on
Dowex-5OH provided 3-aryl and 3-aikyl Aze derivatives 1.31 b-d (Scheme 1.8).
Unsubstituted Aze 1.31 a was also prepared in a similar manner using allyl brornide.
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1. LiOH, THF
RBt, Zn 0 R 2. CCI3
sat. aq. NH4CI, THF HN0t-Bu t-Bu0N--
HNoBn 3. CbzCI, CH2CI2-sat.
0 0 aq. NaHCO3 Cbz’ OBn
1.27 1.28
1. 03, MeOH, -78°C for bd
0s04 Na104, -78°C THF for c
I 3N HCI, rt
.1 O-Otu
O R NaHCO3, R CD Me ChromatographyLIAI(Ot-Bu)3H, CH2CI2 for c,d MeOH/H20, reflux 2 (DOwex 50 H)
3. MsCI, pyridine, DMAP,
- NH.MsOH
CH2CI2 NH2.MsOH
4. H2, Pd/C, MsOH, MeOH 1.29 1.30
R CO2H a)R=H
1.31,adRz
L_NH R= C10H7
U) R i-Pr
Scherne 1.8: Synthesis ofPhe-Aze, Nal-Aze, and Leu-Aze chirneras
1.4.1.2 Synthesis of the Glu-Aze chimera, (-)-traiis-2-carboxyazetidine-3-acetic acid
(t-CAA):
3-Carboxyrnethyl Aze, a Glu-Aze chirnera was synthesized by allylation of a j3-lactarn
enolate derived from D-aspartic acid, subsequent olefin oxidation and lactam reduction.
D-Asp was transforrned via its dibenzyl ester into f3-lactam 1.32. Lactam 1.32 was
converted to its N-sily) lactam and hydrogenated to give N-silyl f3-lactam 4-carboxylic
acid 1.33, which was treated with two equivalents of LDA to form the coiresponding
dianion, which was alkylated with allyl brornide. Esterification using diazomethane and
silyl group cleavage provided allyl -1actam methyl ester 1.34. The lactam and ester
moieties were reduced sirnultaneously with DIBAL-H. The azetidine nitrogen was
reprotected by carbobenzyloxylation, and the alcohol was oxidized to the corresponding
acid. The double bond of acid 1.35 was subjected to ozonolysis, and the resulting
1.26
Chapter 1 23
aldehyde was oxidized with 02 /Pt02 to afford the N-protected azetidine diacid. Rernoval
of the Cbz group by hydrogenolytic cleavage gave the desired azetidine diacid 1.36
(SchemeÏ.9). The (+)-isomer of 1.36 was prepared in an identical fashion starting from
L-aspartic acid. t-CAA was found to be an inhibitor of Natdependent Glu uptake (5 tM)
and to act as a kainic acid receptor agonist (0.7 jiM).
C02H 1. BnOH, p-Ts0H, PhH, reflux,
H02C”
aq. Na2CO3
NH2 2. TMSCI, Et3N, Et20, 0°C,
D-Aspartic Acid t-BuMgCI, 0°C, overnight,
2 N HCI saturated with NH4CI
1. 03, CH2CI2, MeOH, -78°C
Me2S, -78°C to rt
021Pt02 H20, acetone, 40°C
2. H2 5%Pd/C, MeOH, H20
CO Bn • TBDMSCI, Et3N, THF,2 DMAP, rt, H2, Pd/C, Me0H
NH 2. LDA, ether, 0°C,
allyl bromide, 0°C, iN
1.32 KHSO4
1. DIBAL-H, THF, reflux,
CICO2Bn, Et3N, 0°C
2. Jones oxidation
1.36 f-)-t-CAA
Scherne 1.9: Synthesis of (-)-trans-2-carboxyazetidine-3-acetic acid.
1.35
CO2H
1. CHN, Et20, 0°C,
2.1 NHCI,MeOH,H20
TBDM8
Ç,sC02Me
-NH
o
1.33 1.34
(C02H
LN
Cbz
CO2H
N
H
1.4.1.3 Synthesis of (2R,3S)- and (2S,3R)-azetidine-2-carboxylic acids 1.41:
(2R,35)- and (28,3R)-Methoxy-3-phenylazetidine-2-carboxylic acid 1.41 were
synthesized from the commercially available enantiornerically pure arnino diol 1.37 and
D-serine 1.38, respectively (Schernel.10).85 Using a stereoselective photochernical ring
closure of the amino ketone 1.39 and arnino alcohol 1.40, enantiopure (2R,3S)- and
(2S,3R)- azetidines 1.41 were obtained in 71% yield.
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HO O
Ph”NOH
7 steps
PhNOTDS
hv MeO,
MeO..CO2H
H2 Ph[l OTDS L_NH
(‘k CH3 N..Cbz (2R 3S)-1 .41
1.37 1.39 24.6% overall
HO2COH
l0steps
PhOTDS
hv
MeOOTDS MeOCO2H
Cbz CH3 Cbz
1.38 1.40
(2$3R)-1.41
9.6% overaflTDS = (thexyl)(dimethyl) silyl
Scheme 1.10: Synthesis of3-substituted (2R,3S)- and (28,3R)-Aze 1.41.
1.4.1.4 Synthesis of the Val-Aze chimera, 3,3-dimethyl-azetidine 2-carboxylïc acïd
In the course of syntheses of 3,3-dirnethy1ated arnino acid building blocks, f3,f3-dirnethyl-
Aze 1.45 was synthesized from N-(PhF) aspartate dimethyl ester 1.42. N-PhF- f3,f3-
dirnethyl D-Asp dimethyl ester 1.43 was obtained by diaikylation of dirnethyl aspartate
1.42 using methyl iodide and KHMDS in THF in 91% yield. Regioselective reduction of
the 3-methyl carboxylate of N-PhF-f3,f3-dirnethyl-D-aspartate 1.43 to ,f3-dimethyl-D-
hornoserine 1.44 was achieved using DIBAL-H in DCM. Activation of the resulting
alcohol to the colTesponding mesylate, followed by intrarnolecular nucleophilic
dispiacement gave f3,f3-dimethyl-Aze 1.45 (Schernel .1 1)86
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OH
CO2Me MeCOM Me
KHMDS Me-J DIBAL-H Me
Mel, 91° PhFHN’CO2Me —40°C, DOM, PhFHN”CO2Me
89%
1.42 1.43 1.44
Me Me
1.MsCI, TEA,
‘CO2Me
2.A 60% N
PhF
1.45
Scheme 1 .11: Synthesis of f3,3-dirnethy1-Aze
1.4.1.5 3-Phenyl Aze from fi-amino alcohol 1.46:
Enantiopure 3-phenyl Aze was synthesized from 2-cyano azetidines starting from
phenylglycinol.87 (R)-N-Benzyi phenylglycinol 1.49 was prepared tbrough reductive
aikylation, and then cyanornethylated in a two-step procedure involving ring opening of
intermediate oxazolidines 1.4$ with citric acid and KCN/EtOH. Chlorination of the
cyanornethylated arnino aicohol 1.49 with two equivalents ofthionyi chloride in DCM at
0°C produced the reananged chloride 1.50. This rearrangement involves concerted
nucleophilic attack of the chloride anion at the benzylic carbon of aziridinium
intermediate.88 Cyclization ofchloride 1.50 was next affected by treatment with LiHMDS
in THF at -78°C to afford 2-cyano azetidines 1.51 and 1.52 as a 3:7 mixture of
stereoisomers at C(2). Hydrolysis of 2-cyano azetidine 1.52 by using concentrated HC1
(35% wt.), followed by debenzylation ofthe corresponding hydrochioride sait with PdJC,
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and purification by ion exchange chromatography, yielded 3-phenyl Aze 1.53 that can be
considered as a conforrnationally constrained analog ofphenylalanine (Scherne 1.12).
OH 1) PhCHO OH CH2O/toluene o citric acid, OH
Ph,, CI
C 2) NaBH4/EtOH C Dean-stark C > C 1) SOCI2/CH2CI CPh” NH2 Ph” NH N KCN/EtOH Ph” N CN 2) NaHCO3/H20
Bn Bn Quant. Bn1.46 1.47 1.48 1.49 1.50
Ph_CN 1) 35% HCI, 80°C,
COI4, 7days Ph_CO2H
LiHMDS, IHF, -78°C
‘Bn Quant.
94% 151 2) H2, PdIC, then ‘H
+ DOWEX( 50X8-200) 1.53
Ph4N 78%
1.52
Scherne 1.12: Synthesis of enantiopure 3-phenyl Aze 1.53 as a phenylalanine chimera.
1.4.1.6 Asymmetrïc synthesis of 3-substituted Aze employïng SAMP/RAMP
methodology:
Very recently Enders et al. reported the preparation of substituted azetidine type c- and f3-
amino acids via 1 ,3-arnino alcohols by ernploying SAMP/RAMP-hydrazone
rnethodology.89 The SAMP/RAMP hydrazones 1.54 were hydroxyrnethylated by cL
aikylation with (2-trirnethylsilylethoxy)rnethyl chloride (SEMC1). The phenyl substituent
was introduced by nucleophilic 1,2-addition of phenylcerium reagent to the C=N double
bond ofhydrazones 1.55. The hydrazines 1.56 were directly subrnitted to a reductive N-N
bond cleavage to rernove the chiral auxiliary. Tosylation of O-protected amino alcohols
with toluene sulfonyl chloride in the presence of K2C03 at reflux yielded N,O-protected
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amino alcohol 1.57. The amino alcohols 1.58 were cyclized under Mitsunobu conditions
and the corresponding N-tosylated 2-phenylazetidines 1.59 were obtained as one
diastereorner without racernization in good yields. Conversion of2-phenylazetidines 1.59
to the corresponding a-amino acids was accomphshed by catalytic oxidation with
nithenium tetroxide in a biphasic solvent system CH3CN, H20 and CC14. Detosylation
with sodium naphthalene gave the free a-amino acid 1.60 (Scheme 1.13).°
LDA, THF, 0°C, then PhLI, CeCI3,
N. -100°C, SEMCI, 66-77% NN THF, -105°C
HO-I
HH
HO
(S)-1.54 R= Me, Et, i-Pr, n-Bu 155
1) BH3.THF, THF, Ts
\N. reflux, then HCI HN’
H0 i—0,—-Si(CH3)3
54-64% over two steps Çj7
(S,R)-1 .57
f S,R,S)-1.56
LBF M CN H HN’
DIAD, PPh3, THF, 1) RuCI3, H5106,
(8:2’, relux
2
[DH
r.t., 86-94%
2)NnaphaIene,
t.
51 65% over two steps
(S,R)-1.58 (S,S)-1.59
HO2CR
(S,S)-1 .60
R= Me, Et, i-Pr, n-Bu
Scheme 1.13: Synthesis of 3-substituted Aze by employing SAMP/RAMP-hydrazone
methodology.
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1.4.2 Synthesis of 4-substituted azetidine-2-carboxylic acids
Introduction:
4-substituted azetidine 2-carboxylic acids with one or two carboxy groups have been
found in natural products91 and rigid glutamate analogues with metabotropic receptor
activity.84 For example, cis-2,4-azetidine dicarboxylic acid is a nonproteinogenic amino
acid that bas been reported as a neurotransmitter potentiator.92’93 Red-rnold rice is
effective in decreasing blood pressure and lowering plasma cholesterol levels and bas
antibacterial activity. 96 Recently, (+)-monascumic acid 1.61 and (-)-rnonascumic acid
1.61 were isolated from red-mold rice (Figure 1.1
H02C%<>002
H
“002 H
(2S,4R) (2R,4S)
1.61 (2S,4R)or(2R,4S)
1.61 (2R,4S)or(2S4R)
Figure 1.11: Structures of cis-2,4-azetidine dicarboxylic acid from exracts of red-mold
rice.
Moreover, 2,4-disubstituted azetidines with hydroxymethyl groups have been used as
chiral auxiliaries97 and catalysts98 for asymrnetric synthesis, and have been prepared from
the corresponding 2 ,4-azetidine dicarboxylic acids
1.4.2.1 Synthesis of 4-trifluoromethylated azetidine -2-carboxylic acid:
A diastereoselective synthesis of 4-trifluorornethylazetidine-2-carboxylic acid 1.67 was
accomplished by the Wittig reaction of 4-trifluoromethyl f3-lactam 1.63 followed by
hydrogenation and ftinctional group transformations.10° 4-Trifluoromethyl-f3-lactam 1.63
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was prepared from the cornmercially available f3-amino acid 1.62. Without purification,
the lactam was treated with (Boc)20 in the presence of 10% mol DMAP to afford N-Boc
protected f3-lactarn 1.63 in 25% overali yield from acid 1.62. The Wittig reaction with
ylide and lactam 1.63 in toluene at reflux afforded enamine 1.64. Hydrogenation of the
C=C bond of enarnide ester 1.64 over Pd/C in ethyl acetate afforded exclusive cis-2,4-
substituted azetidine 1.65 in 92% yield. 4-trifluorornethylazetidin-2-yl olefin 1.66 was
prepared from ester 1.65 in 3 steps by ester hydrolysis, carboxylate reduction via a mixed
anhydride and elirnination of the prirnary alcohol. Subsequent oxidation of olefin 1.66 to
the carboxylic acid 1.67 was accomplished using Na104/ RuC13 in 80% yield (Scheme
1.14).
NH 1.TMSCI/TEA
_JCO2H 2. CH3MgBr ,,[1 Ph3P=CHC02Me CH2C02MeF3C 3. (Boc)20/DMAP N toluene, 85%
F3C CO2tBu F3C CO2tBu
1.62 1.63 1.64
1. Na0H 00 H
H2/Pd, AcOEt
CH2C02Me 2. t-Bu0C0CI, NaBH4 Na104/RuCI3 2
92% 3. 2-CI-C6HSeCN 80%
F3C ‘CO2tBu PBu3, H202 F3C ‘CO2tBu F3C CO2tBu
1.65 1.66 1.67
Scheme 1.14: Synthesis ofN-Boc-4-trifluorornethyl Aze.
1.4.2.2 Selectïve azetïdine formatïon via Pd-catalyzed cyclizations of allene
substituted amines and amino aciils:
4-Substituted Aze analog 1.73 was obtained in enantiornerically enriched form by
enzymatic resolution of w-allenyl amino acid 1.70 followed by Pd-catalyzed ring
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annulation (Scherne 1.15)101 The hydrochioride sait of allenyl amino ester 1.69 was
synthesized via aikylation of the giycine-derived ketimine 1.6$ with 4-brorno-1,2-
butadiene, fo]lowed by acid hydrolysis of the irnine. Reaction of the ester with aqueous
ammonia afforded the amino amide 1.70. Enzymatic resolution of the (5-arnide 1.70
with F.putida ATCC 12633 provided the (S)- acid 1.71 in 82% ee. Subsequentiy, the (R)
amide was hydrolyzed with RH. erthropoÏis NCYB 11540 to provide (R)-1.71 in 98% ee.
Application of different cyclization conditions using Pd(PPh3)4, and K2C03, with aikenyl
or aryl halides, and triflates in DMF Iead to different ratios of four and six membered
rings (Scheme 1.15).
Chapter 1 31
1)Br
Ph NaH
PhNCO2Me
2)1 N HCI, 80%
HCI.H2N CO2Me1.68
L
XH
H2N
o
RH. erythropolis R-1.70, X= NH
NCIB 77540 R-1.71, X O, 98%ee
Pd(PPh3)4
‘CO2Me
K2003, R1X N
DMF, heat Ts
R1X
Phi
tBu0Tf
tBu )LOTf
Ratio cf 1.73:1.74
88:12, a
88:12, b
95:5, c
Scherne 1.15: Azetidine formation via Pd-catalyzed cyclization
1.4.2.3 Synthesis of azetidine-2,4-dicarboxylïc acïd
A diastereoisomeric mixture of azetidine 2,4-dicarboxylate 1.76 was synthesized by
heating dirnethyl 2 ,4-dibrornopentanedioate 1.75 with (S,)- 1 -phenylethylamine in toluene
containing aqueous potassium carbonate (Scherne 3.3). Three components (S,5-1.76
(22%), (R,R)-1.76 (22%) and cis-1.76 (44%) were separated by flash chrornatography.
NH3, H20
75%
H2
N H2
1.70
P. putida ATCC 72633
PH: 8.5, 37°C
1.69
‘C02Me
+ H20H Ts
o
S- 1.71, 82%ee 1.72from 1.71
R1
+
1.73 1.74
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Hydrogenolysis of diester (S,S)-1.76 over palladium hydroxide on carbon followed by
hydrolysis in hot water afforded (2S,4S)-azetidine-2,4-dicarboxylic acid 1.77 (Scherne
102 The (R,R)-isorner was also prepared by the sanie reaction sequence from
diester (R ,R)-1 .76.
NH2
Br /“H 1H2, Pd(OH)2
COMe Ph Me MeO2C1Ç,>CO2Me 2. H20, reflux
Ho2c.<”)—co2H
COMe K2C03,Toluene/H20 Ph»H
Br reflux, 20h, 83% Me
1.75 (S,S)-1.76 (S,S)-1.77
Scherne 1.16: Synthesis of azetidine-2,4-dicarboxylates.
1.4.2.4 Synthesis of 4-substituted Aze via Wittig reaction of monocyclic lactams:
Substituted 2-exo-methylene azetidines were synthesized by a Wittig reaction on f3-
lactam 1.78 (Scherne 1.17). The resulting compounds were subjected to a range ofylides.
Substimted 2-exo-methylene azetidines 1.79 were prepared using stabilized ylides. The
unstabilized ylides or Horner-Emmons reagents led only to decomposition of starting
material. 103
CO2Bn
CO2Bn fl’
Wttig reagents R1NSBQc
Boc R2
1 78 1.79, a. R1=
CO2Et, R2= H, 80%
b. R1= CO2tBu, R2= H, 98%
c. R1= CN, R2= H, 53%
d. R1= CO2Et, R2= Me, 50%
Scheme 1.17: Synthesis of4-olefin Aze via Wittig reaction ofmonocyclic lactams
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Exciuding the intensely studied Ç3-lactams, few syntheses of substituted azetidines have
been reported. The reported yieMs of Aze analogues have been typically poor. Methods
for synthesizing substituted Aze are also limited by the availability of the starting
materials and cannot daim wide applicability. Therefore, the synthesis of substituted Aze
remains a challenging problem for which new methodology is required.
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2.1 Abstract
Azetidine 2-carboxylic acid (Aze) analogs possessing various heteroatomic side chains at
the 3-position have been synthesized by modification of 1-PhF-3-allyl-Aze tert-butyl
ester (2S,3S)-2.1 (PhF = 9-(9-phenylfluorenyl)). 3-Allyl-Aze 2.1 was synthesized from a
sequence commencing with regioselective allylation of Œ-tert-butyl f3-rnethyl N
(PhF)aspartate 2.13, followed by selective w-carboxylate reduction, tosylation and
intramolecular N-alkylation. Rernoval of the PhF group and olefin reduction by
hydrogenation followed by Frnoc protection produced nor-Leucine-Aze chimera 2.2.
Regioselective olefin hydroboration of (2S,35)-2.1 produced primary alcohol 2.23, which
was protected as a silyl ether, hydrogenated and N-protected to give 1-Frnoc-3-
hydroxypropyl-Aze 2.26. Enantiopure (2S,3 S)-3 -(3 -azidopropyl)- 1 -Fmoc-azetidine-2-
carboxylic acid tert-butyl ester 2.3 was prepared as a Lys-Aze chirnera by activation of 3-
hydroxypropyl-Aze 2.26 as a methanesulfonate and dispiacernent with sodium azide.
Moreover, orthogonally protected azetidine dicarboxylic acid 2.4 was synthesized as an
a-arninoadipatc-Aze chimera by oxidation of alcohol 2.26. These orthogonally protected
amino acid-Aze chirneras are designed to serve as tools for studying the influence of
conformation on peptide activity.
Key words: azetidine 2-carboxylic acid; azetidines; amino acid; chimera; heterocycle;
peptide synthesis
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2.2 Introduction
Conformationally constrained amino acids have been used as tools for studying peptide
secondary structure and for developing peptide-derived pharmaceutical agents.’4 In
particular, cyclic amino acids such as proline and its higher homologue pipecolic acid
have been used to restrict the phi and psi dihedral angles of the peptide backbone to
induce tum geometry.5’6 Furthermore, the introduction of -substituents onto proline and
pipecolate has been used to create arnino acid chimeras, which can restrict the side-chain
orientations and backbone geometry of specific residues within a peptide to study the
relationship between conformation and activity. for example, proline-amino acid
chirneras have been used in place of natural amino acids in peptides to provide a better
understanding of the bioactive conformations of G-protein coupled receptor (GPCR)
ligands 7-10 and peptide-based enzyme inhibitors.
Azetidine 2-carboxylic acid (Aze) has been used less often as a probe for studying
peptide chernistry and biology. Aze has been incorporated in vivo and in vitro into
cellular proteins of Escherichia cou 12 as well as in chick embryo’3 for studies on
collagen biosynthesis, 14 in which replacement of Pro in collagen with as little as 4% of
Aze was sufficient to destabilize triple-helix bundle formation. The study of Aze in
polypeptides such as poly-L-Aze, has shown that peptides containing Aze are more
flexible than the corresponding sequences containing Pro and that the tendency for f3-
bend formation is higher for Gly-Aze than for Gly-Pro dipeptides. 1518 Introduction of
Aze into a peptide containing three consecutive proline residues in a linear sequence
perturbed the normal proline peptide secondary structure and the cis-trans amide isomer
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equilibrium in Boc-(L-Pro)3-L-Aze-Opcp (pcp pentachlorophenyl).’9 Replacernent of
Aze for proline in peptide analogs lias also altered receptor selectivity. 20
A component of biologically and pharmacologically important natural products and
synthetic cornpounds, Aze is found in the polyoxin group of antifungal antibiotics, 21
nicotianamine, 22 mugineic acid 23 and red-rnold rice fermentation products. 24 Among
substituted azetidine carboxylic acid analogs, cis-azetidine-2,4-dicarboxylic acid lias been
reported as a neurotransmitter potentiator 25,26 and trans-2-carboxyazetidine-3-acetic acid
(t-CAA) lias been used as a rigid glutamic acid analog exhibiting effects such as
inhibition of Natdependent Glu uptake and neuroexcitatory activity at the kainate
receptor sub-type. 26
In the context of our research on the effects of azacycloalkane amino acids on peptide
conformation, we became interested in empÏoying f3-alkylazetidines as azetidine-arnino
acid chimeras for studying secondary structure. In light of its importance as a constituent
of biologically active cornpounds, the development of rnethodology for synthesizing Aze
analogs is rnerited; however, relative to proline and pipecolate analogs the synthesis of
alkyl-substituted azetidine 2-carboxylic acid derivatives lias received less attention. Few
methods have offered the potential for selective and stereocontrolled introduction of alkyl
substituents at the ring carbons. Earlier syntheses of racemic 2-azetidine carboxylic acids
by resolution and by a series of transformations starting from homoserine have been
reviewed.2729 Azetidine-2-carboxylic acids have been synthesized bearing substituents at
the l_3037, 2— 38-42 21,43-50 and 4—positions,5’ as well as with multiple substitution
patterns. 52-55
Chapter 2 45
Synthesis of the azetidine ring is typically achieved by intramolecular cyclization of the
open-chain cornpounds to form the C-N bond. 27,56 At the tirne of our investigation, we
were aware of five methods for the synthesis of 3-substituted azetidine-2-carboxylates in
enantiopure forrn. For example, 3-substituted L-azetidine 2-carboxylic acids possessing
phenyl, naphthyl and isopropyl substituents at the 3-position were synthesized by
Hanessian and co-workers using a general route featuring diastreoselective zinc-mediated
additions of substituted allylic halides to the camphor sultam derivative of glyoxalic acid
O-benzyl oxirne, followed by a series of transformations to convert the linear a-arnino
pentenamide product into the 3-aryl and 3-aikyl Aze derivatives 2.5-2.7 (fig. Both
cis- and trans-polyoximic acids were also synthesized by the Hanessian Iab starting from
D-serine as a chiral educt. 21,46 In addition, 3-acetic acid (t-CAA) and 3-propionic acid
analogs 2.8 and 2.9 of Aze have been synthesized by allylation of a 3-1actam enolate
‘6denved from D-aspartic acid and subsequent olefin oxidations and lactam reducnon.
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CO2H CO2H
CO2H
R = Amino acid side chain Polyoximic Acid
Aze, n = O Aze-Xaa chimera, n = R1 Me R2 = H trans
Pro, n = 1 Pro-Xaa chimera, n = 1 R1 = H R2 = Me cisPip, n = 2 Pip-Xaa chimera, n = 2
)—N3 CO2H
(»CO2tBu (>—CO2tBu (>—‘CO2tBu
N N N
Fmoc Fmoc Fmoc
Nie-Aze Lys-Aze Œ-Aminoadipate-Aze
chimera 2.2 chimera 2.3 chimera 2.4
Y
N N N
H H H
Phe-Aze Nal-Aze Leu-Aze
chimera 2.5 chimera 2.6 chimera 2.7
HO2C
002H z> Me Me
Ç.ICO2H CO2H
hF
Glu-Aze chimera Œ-Aminoadipate-Aze Val-Aze
(t-CAA) 2.8 chimera 2.9 chimera 2.10
Figure 2.1: Representative Aze-Xaa arnino acid chirneras.
Among the strategies for making 3-substituted Aze analogs, the synthesis of 3,3-
dirnethyl-Aze 2.10 by Goodman seerned practical,47 because it employed N-
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(PhF)aspartate dimethyl ester 2.11, which could be prepared by regioselective aikylation
using rnethodology introduced by Rapoport for the installation of various side-chain
groups (57). 3,3-Dirnethyl-Aze 2.10 was prepared from i3,f3-dimethyl aspartate 2.11 by
regioselective reduction of the 13-methyl carboxylate, activation of the resulting alcohol
and intramolecular nucleophulic dispiacement (Fig. 2.2). ‘
OH
Me Me
MeCO2Me DIBAL-H Me
‘CO M —40°C, DOMPhFHN’ 2 e PhFHN’ CO2Me
2.11 2.12
Me Me
MsCI,TEA, A
‘CO2Me
PhF
2.10
Figure 2.2: Synthesis off3,3-dirnethyl-Aze by Goodman.47
Azetidine 2-carboxylic acids possessing heteroatornic side-chain substituents at the 3-
position were thus targeted, using a-tert-butyl 3-rnethy1 N-(PhF)aspartate 2.13 as a
common interrnediate. Regioselective enolization and aikylation of aspartate 2.13 was
considered for introducing allyl substituents stereoselectively at the f3-position.57’58
(23,35)- and (2S,3R)-3-Allyl 1-PhF-Aze tert-butyl ester 2.1 were synthesized in 4 steps
from f3-allyl aspartate 2.19 by a route featuring selective w-carboxylate reduction and
intramolecular N-alkylation (Fig. 2.4). (23,35)-Olefin 2.1 was subsequently used as a
common interrnediate for the synthesis of a series of azetidine-arnino acid chimeras
involving hydrogenation or hydroboration of the olefin to provide constrained nor
leucine-Aze chirnera 2.2 and 3 -hydroxypropyl-azetidine-2-carboxylate 2.23, respectively
Chapter2 48
(Fig. 2.6). Conversion ofPhF-azetidine 2.23 into its Fmoc counterpart 2.26, activation of
the hydroxyl group and dispiacement with azide gave Lys-Aze chirnera 2.3 (Fig. 2.7).
Oxidation of alcohol 2.26 provided Œ-aminoadipate-Aze chimera 2.4.
2.3 Resuits and discussion:
a-tert-Butyl f3-methyl N-(PhF)aspartate 2.13 was synthesized in three steps on a 15 g
scale from L-aspartic acid according to a literature method. The parent arnino acid, Aze
was first prepared to compare the reactivity of diaikyl, monoalkyl and cornpounds
lacking a substituent at the 3-position during the cyclization step. w-Ester reduction with
DIBAL-H in tetrahydrofuran (THF) at —40 oc provided the corresponding homoserine
2.14 without lactone formation (Fig. Hornoserine 2.14 was then converted to the
corresponding tosylate 2.15 in 72% yield by using toluenesulfonyl chloride and pyridine
in dichiorornethane (DCM). Under these conditions, concurrent intramolecular ring
closure occun-ed to provide azetidine 2.16 as an additional product in 16% yield after
cbromatography. In our hands, the intrarnolecular dispiacement was best effected using
Cs2CO3 in acetonitrile; Na2CO3 in acetonitrile gave a siower reaction and lower yield.
Frnoc-Aze-OtBu 2.18 was synthesized in two steps and 77% yield from N-PhF-Aze 2.16.
Hydrogenation of 2.16 at $ atm of H2 using palladium-on-carbon as catalyst in 9:1 EtOH:
AcOH gave the amino ester which was isolated as its HCY sait. The Fmoc group xvas then
installed using FmocOSu and sodium bicarbonate in acetone/H20 at room temperature.
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CO2Me DIBAL-H, -40°C, THF
PhFHN CO2tBu
2.13
TsCI, pyridine, CH2CI2 j 2.14: R = H(92%)
2.15:R= Ts
[(72%) + 2.16 (16%)]
1) Pd/C, H2, 8 atm,
Cs2003,CH3CN, COtBu 9:1 EtOH:AcOH
PhF 2)HCI(aq)
2.16 (58%)
FmocOSu,NaHCO3( 2:1 acetone:H20
CO2tBu (‘>—‘CO2tBu
N N
HHCI Fmoc
2.17 2.18 (77%)
figure 2.3: Synthesis ofFmoc-Aze-OtBu 2.18 from aspartate 2.13.
3-Allyl-1-(Phf)-azetidine-2-carboxylic acid tert-butyl esters 2.1 were synthesized in a
sirnilar manner using 3-a11y1 aspartate 2.19 (Fig. 2.4). Regioselective aikylation ofa-tert
butyl t3-methyl N-(Phf)aspartate 2.13 was achieved using sodium
bis(trimethylsilyl)amide (NaHMDS, 1M in THF) followed by reaction with allyl iodide,
which produced a 3 : 2 mixture of diastereomers 2.19 in 96% yield after chromatography.
The unseparated mixture of diastereomers were reduced with DIBAL-H in THF at —40 oc
to provide homoserine diastereorners (23,3]?)- and (23,33)-2.20 in 91% yield after
chromatography. The mixture of diastereomeric alcohols was separated by performing a
second chromatography using toluene-isopropylether (8 : 2) as eluant. Tosylation and
intramolecular dispiacernent of (2S,3R)- and (23,33)-2.20 were perforrned as described
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for the parent system using toluenesulfonyl chloride and pyridine in DCM and afforded
the corresponding tosylates 2.21, which were then heated with Cs2CO3 in CH3CN to
provide (28,3R)- and (2S,33)-azetidine 2.1, respectively.
CO2Me
PhFHN C02t-Bu
2313
C H H C H21,
NaHMDS, THF,
—78° C
CO2Me
__&yCO2tBu
NHPhF
(2S3RS)-2.19 (96% dr = 3:2)
DIBAL-H, -40°C,
TH F
HO HO
L(CO2tBu + CO2tBu
NHPhF NHPhF
(2S,3R)-2.20 (61%) (2S,3S)-2.20 (30%)
TsCI, pyridine, TsCI, pyridine,
CH2CI2 CH2CI2
TsO TsO
JLCO2tBU _Ç(CO2tBU
NHPhF NHPhF
(2S,3R)-2.21 [ (47%)-i- (2S,3S)-2.21 [(66%)÷
(2S,3S)-2.1 (38%)] (2S3R)-2.1 (21%)]
Cs2CO3, Cs2003,
CH3CN,A C
(>—.CO2tBu CO2tBu
rJ
PhF PhF
(2S,3S)-21 (61%) (2S,3R)-2.1 (52%)
Figure 2.4: Synthesis of3-Allyl 1-PhF-Aze (23,38)- and (2S,3R)- 2.1
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The configurations of the (2S,3R)- and (2S,3S)-3-allyl azetidines 2.1 from cyclization of
the (2S,35- and (2S,3R)- tosylate diastereomers, respectively, were assigned based on
their NOESY spectra in CHC13 (Fig. 2.5). Transfer of magnetization between the a
hydrogen and the allylic methylene protons indicated their cis relationship in (2S,3S)-2.1.
The trans relationship between the allyl group and a-proton in (2S,3R)-2.1 was indicated
by their respective NOEs with the two different y-protons.
HH
H(Q’
H Ni-j
(2S,3S)-2.1
Figure 2.5: Long distance NOE correlations for the stereochemical assignments of
(2S,3R)- and (2S,33)-3-allyl-1-PhF-azetidine-2-carboxylates 2.1 (characteristic transfers
of magnetization are written with double-tipped arrows).
Orthogonally protected nor-leucine-Aze chimera 2.2, suitable for peptide synthesis, was
prepared in two steps and 58% yield from fl-allyl N-(PhF)Aze 2.1 (Fig. 2.6).
Hydrogenation at 6 atrn using palladium-on-carbon as catalyst in 9 : 1 EtOH : AcOH
effected double bond reduction and cleavage of the phenylfluorenyl group. Installation of
the Frnoc group was then accomplished using FmocOSu and sodium bicarbonate in
acetone/H20 at room temperature.
H,
H’
(2S,3R)-2.1
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J 1)Pd/C, H2 (6 atm)
9:1 EtOH:AcOH -
) (aq)
N
CO2tBu 3) FmocûSu,NaHCO3 CO2tBu
I 1:2 H20:acetone I
PhF R
(2S, 3S)-2.1 2.22: R = H HCI
2.2 : R=Fmoc
BH3S(Me)2, (58% from 2.1)
NaOH, H202
<OR 1)TBDMSCI, DMAP, OH) Et3N, CH2CI2 5>2)Pd/C, H2 (8 atm)
9:1 MeOH:AcOH
N
CO2tBu 3)FmocOSu,NaHCO3 N
CO2tBu
PhF 1:2 H20:acetone
2.23: R = H (93%) 2.25: R = H
2.24: R = TBDMS 2.26: R = Fmoc
(66% from 2.23)
Figure 2.6: Reduction and hydroboration of olefin 2.1; synthesis ofNle-Aze chimera 2.2.
The elaboration of olefin 2.1 into a variety of heteroatom-containing side-chains was
initiated by hydroboration and conversion to the corresponding 3-hydroxypropyl-Aze
2.23 (Fig. 2.6). Earlier atternpts to prepare the primary alcohol using disiarnyl borane 60
and 9-BBN in THF, 61 followed by treatment with NaOH and H202, were unsuccessfuÏ
and starting material was recovered. Employing BH3 as a less sterically bulky borane in
THF produced a mixture of primary and secondary alcohols in low yieM. Selective
formation of primary alcohol 2.23 was achieved in 93% yield using borane dimethyl
sulfide complex in THF followed by oxidative work-up.62
The exchange of the nitrogen protecting group from PhF to Fmoc was examined to later
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facilitate oxidative and peptide chemistry. Several solvent systems were examined for the
hydrogenolysis of primary alcohol 2.23 to remove the PhF group, such as 9 1 MeOH
AcOH, 9 1 EtOH AcOH, and THF, using palladium-on-carbon under hydrogen
atmosphere. However, unsatisfactory resuits were obtained. On the contrary, treatment of
3-hydroxypropyl-Aze 2.23 with TBDMSCI in the presence of DMAP and triethylamine
gave 3-siloxypropyl-Aze 2.24, which underwent hydrogenolytic cleavage of the PhF
group in 9 : 1 MeOH : AcOH using palladium-on-carbon under $ atm of H2. 1-Fmoc-3-
Hydroxypropyl-Aze 26 was then prepared by treatment of the hydrogenation mixture
with NaHCO3 and FmocOSu in acetone!H20 at room temperature for 24 h, work-up and
chromatography on silica gel.
Activation of N-Fmoc-3 -hydroxypropyl 2.26 using methanesulfonyl chloride and
triethylamine in dichloromethane gave methanesulfonate 2.27 in 80% yield after
purification by chrornatography (Fig. 2.7). Nucleophilic dispiacernent of 2.27 with
sodium azide in dirnethylforrnamide (DMF) at so oc furnished azide 2.3 in 62% yield. cL
Amino adipate-Aze chimera 2.4 was finally synthesized in 90% yield by oxidation of 3-
hydroxypropyl-Aze 2.26 with a cocktail ofNaclO2, NaOcl and TEMPO in 63
Chapter 2 54
OH <OMs
MsCI, Et3N,
DMAP, CH2CI2
COtBu CO2tBu
r r
Fmoc Fmoc
2.26 2.27 (80%)
NaCIO2, NaOCI, NaN3 DMF A
TEMPO
COOH N3f
(‘)—CO2tBu
Fmoc Fmoc
2.4 (90%) 2.3 (62%)
Figure 2.7: Synthesis of Lys-Aze and a-Amonoadipate-Aze chimeras 2.3 and 2.4.
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2.4 Conclusion:
A series of enantiopure amino acid-Aze chirneras possessing heteroatornic side-chains
have been synthesized starting from aspartate diester 2.13 as an inexpensive chiral educt.
fl-Allylation of diester 2.13 followed by w-ester reduction, tosylation and intramolecular
cyclization gave 3-allyl-1-PhF-Aze 2.1. Olefin reduction and Frnoc-protection provided
nor-leucine-Aze chimera 2.2. Olefin hydroboration afforded the corresponding 3-
hydroxypropyl-Aze 2.23 which was converted respectively to Lys-Aze and a
arninoadipate-Aze chirneras 2.3 and 2.4 by routes featuring alcohol activation and
dispiacement with azide ion and TEMPO-catalysed oxidation. We are currently exploring
the introduction of these amino acid-Aze chimeras into peptides to study structure
activity relationships.
2.5 Experimental Section
General. Unless otherwise noted, ail reactions were run under nitrogen atmosphere and
distilled solvents were transferred by syringe. Anhydrous tetrahydrofuran (THF),
dichioromethane (DCM), acetonitrile (CH3CN) and dirnethylformaide (DMF) were
obtained from solvent filteration systems. Triethylarnine (Et3N) and pyridine were
distilled from ninhydrin and CaH2. Final reaction mixture solutions were dried over
Na2SO4 and rotary-evaporated under vacuum. Melting points are uncorrected. Mass
spectral data, HRMS/ESMS, were obtained by the Université de Montréal Mass
Spectrornetry facility. Unless otherwise noted, 1H NMR (300/400 MHz) and ‘3C NMR
(75/100 MHz) spectra were recorded in CDC1. Chemical shifts are reported in ppm (ô
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units) downfieid of internai tetramethylsilane ((CH3)4Si) or residual solvent: CHCI3 and
MeOH. Coupling constants are reported in hertz (Hz). Chemical shifts of arornatic and
vinylic carbons are flot reported for the ‘3C NMR spectra of PhF containing compounds.
Analytical thin-layer chromatography (TLC) was performed using aiuminum-backed
silica plates coated with a 0.2 mm thickness of silica gel 60 F254 (Merck KGaA
Gennany). Chrornatography was performed using Kieselgel 60 (23 0-400 mesh).
(2S)-tert-Butyl 2- IN-(PhF)Amino] -4-(toluenesulfonyloxy)-butyrate (2.15):
OTs
PhFHN02t
To a magneticaiiy stirred solution of alcohol 2.14 (500 mg, 1.2 mmol, 100 mol %,
prepared according to reference 59) and dry pyridine (1.2 ml) in dry CH2C12 (12 ml) at O
°C, solid p-toluenesulfonyi chloride (693 mg, 3.6 mmol, 300 mol ¾) was added in one
portion. The mixture was stirred at O °C for 2 h and then at room temperature for 24h.
The reaction mixture was poured into ice water and extracted with ethyi acetate (3 x 20
ml). The organic phases were combined, washed with brine, dried (Mg$04) and
evaporated to a residue that was chromatographed using 5% EtOAc in hexanes as eiuant.
First to eiute was azetidine 2.16 (77 mg, 16% yield) as a solid: m.p. 156.5-157.5 C,
spectral properties were identical to those reported beiow. Next to elute was tosylate 2.15
(496 mg, 72% yield) as white crystals: m.p. 106-107 °C; [a]20D —184.3° (c 0.01; CHCI3).
‘HNMR 6: 1.21 (s,9 H), 1.51-1.62 (m,1 H); 1.72-1.82 (m,1 H); 2.47 (s,3 H); 2.52-2.55 (t,
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J= 5 Hz, 1 H); 3.09 (s, 1 H); 4.03-4.10 (dd, J° 13.16; 6.68 Hz, 1 H), 4.21-4.23 (dd, J
16.1; 7.1 Hz, I H); 7.20-7.85 (m, 17 H). ‘3C NMR ô 22.1; 28.1; 34.4; 53.1; 68.0; 73.2;
8 1.7; 174.44. ESMS m/z 592.1 (M+Na).
(2S)-tert-Butyl 1-(PhF)-azetidine-2-carboxylate (2.16):
COtBu
PhF
A vigorously stirred mixture of tosylate 2.15 (500 mg, 0.877 mrnol, 100 mol%), and
powdered Cs2CO3 (430 mg, 1.31 mrnol, 150 rnol%) in 10 ml of acetonitrile was heated
at reflux under argon for 19 h and evaporated. The residue was treated with ice-water
(10 ml), and extracted with EtOAc (3 x 20 ml). The combined organic phases were
washed with brine, dried (MgSO4) and evaporated to a residue that was purified by
chromatography using an eluant of 3% EtOAc in hexanes. Azetidine 2.16 (202 mg, 58%
yield) was obtained as white crystals: rn.p. 156.5-157.5 °C. {a]20D 38.50 (c 0.01, CHCÏ3).
‘H NMR ô 1.13 (s, 9H); 1.72-1.82 (ni, 1 H); 2.03-2.15 (m, Ï H); 3.10-3.18 (dd, J = 15.6;
8.2 Hz, 1 H), 3.25-3 .36 (rn, 2 H); 7.13-7.68 (m, 13 H). ‘3C NMR ô 20.8; 28.1; 46.7; 60.8;
76.5; 80.3; 172.4. ESMS mlz 398.1 (M+H). HRMS calcd. for C27H27N02 (M+H)
398.21146, found 398.21153.
Azetidine-2-carboxylïc Acid tert-Butyl Ester Hydrochioride (2.17):
C>— CO2tBu
N
HHCI
A solution ofPhF-Aze 2.16 (322 mg, 0.81 rnrnol, 100 mol%) in 30 ml ofEtOH:HOAc
Cliapter2 5$
(9:1) was transferred into a hydrogenation apparatus and treated with palladium-on
carbon (32 mg, 10 wt %). The pressure bottie was fihled, vented, and refihled four times
with hydrogen. The reaction mixture was stirred for 24 h at 6 atm of H2, filtered onto a
p!ug of CeÏiteR 521(Aldrich USA), and washed thorough]y with EtOH. The filtrate was
treated with 1m] of iN HC1 and the volatiles were evaporated to give a cmde residue
(125 mg) that was used directly in the Fmoc protection without purification. ‘H NMR of
crude 2.17: t3 1.41 (s, 9 H); 2.56 (s, 1 H); 2.77 (s, 1 H); 4.15 (d, J 37.2 Hz, 2 H); 4.75
(s, 1 H); 5.00 (s, 1 H). ‘3C NMR 6 22.9; 27.9; 43.5; 57.5; 84.5; 166.9. ESMS rn/z 157.9
(M)
tert-Butyl 1-(Frnoc)-Azetidine-2-carboxylate (2.18):
CO2tBu
N
Fmoc
Frnoc-Aze 2.18 (295 mg, in 77% yield) was synthesized from Aze 2.17 (147 mg, 0.93
mmol) using the general Fmoc protection protocol described below and purified by
chromatography using an eluant of 3-11% EtOAc in hexanes. Evaporation of the
collected fractions gave 2.18: [Œ]20D —78.9 0 (e 0.03, CHC13). ‘H NMR 6 1.50 (s, 9 H);
2.17-2.25 (m,1 H); 2.53-2.62 (m, 1 H); 4.00 (d, J = 6.21 Hz, 1 H); 4.10-4.38 (m, 4 H);
4.64 (d, J = 4.6, Hz, 1 H); 7.30-7.77 (m, $ H). ‘3C NMR 6 20.8; 28.0; 47.2; 50.3; 65.1;
67.3; 81.8; 119.9; 125.2; 127.0; 127.7; 141.4; 144.5; 155.8; 170.3. ESMS m/z 402.1
(M+Na). HRMS calcd. for C23H25N04 (M+Na) 402.16758, found 402.16822.
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Œ- tert-Butyl -MethyI f3-Allylaspartate (2.19):
Diester 2.13 (11.16 g, 25.16 mmol, 100 mol% prepared according to reference 59) was
dissolved in 230 ml of dry THF, cooled in an acetone/dry ice bath to —78 °C, treated
dropwise with NaHMDS (26.4 ml ofa 1M solution in THF, 105 mol%), stined at —78°C
for 1h, treated with allyl iodide (4.6 ml, 50.3 mmol, 200 rnol%), and stirred for 2h. The
cold reaction mixture was quenched with methanol (25 ml) and 1M NaH2PO4 (60 ml),
allowed to warm to room temperature, and extracted (3 x 100 ml) with ethyl acetate. The
combined organic phases were washed with brine, dried over Mg$04 and concentrated to
a residue that was chromatographed using 3-5% EtOAc in hexanes as eluant. Evaporation
of the collected fractions gave a mixture of two diastereomers in a 3:2 ratio as assessed
by measurement of the diastereomeric methyl ester singlets in the NMR spectrum (11.63
g, 95% yield). ‘H NMR for the major diastereorner: ô 1.26 (s, 9 H); 2.09-2.17 (m, 1 H);
2.43-2.67 (m, 2 H); 2.87- 2.96 (ni, 1 H); 3.27- 3.37 (d, J= 9.4 Hz, 1 H); 3.70 (s, 3 H);
5.00-5.06 (m, 2 H); 5.66-5.75 (rn, 1 H); 7.24-7.74 (m, 13 H). ‘3C NMR ô 28.0; 32.5; 50.8;
5 1.5; 57.1; 57.9; 72.9; 77.6; $ 1.5; 172.9, 173.0. ESM$ m/z 484.1 (M). HRMS calcd. for
C31H33N04 (M+H) 484.24824, found 484.24852.
(2S,3S)- and (2S,3R)-3-Hydroxymethyl-2-[(PhF)amino] -hex-5-enoic Acid tert-Butyl
Ester (2.20):
To a stirred solution of alkylated diester 2.19 (11.63, 24.06 mmol, 100 mol%) in THF
(484 ml) at -40 °C, DIBAL-H (72.2 ml of a 1M solution in THF, 300 mol %) was added
and stirring was continued for 3h. The mixture was treated with acetone (15 ml) to
quench excess hydride, diluted with methanol (50 ml), allowed to warni to room
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temperature and evaporated to a residue that was dissolved in ether (500 ml) and washed
with NaOH 1M (3 x 150 ml). The combined organic layers were washed with brine,
dried, filtered, and evaporated. The residue was first chrornatographed with 5-10%
EtOAc in hexanes to provide a mixture of diastereomers, that were separated by
performing another column using toluene-i sopropropylether (8:2) as eluant.
Minor diastereorner (2S,3S-2.2O (3.4 g, 30% yield) eluted first: [Œ]20D —327.3° (c 0.01,
CHC13). ‘H NMR 6 1.25 (s, 9 H); 1.62-1.66 (ni, 1 H); 1.96-2.05 (rn, 1 H); 2.17-2.25 (m, 1
H); 2.79 (d,J’ 3.2 Hz, 1 H); 3.55 (s, 1 H); 3.49 (dd,J= 11.1; 8.0 Hz; 1H); 3.63 (dd,J
= 11.0; 4.3 Hz, I H); 4.89-5.03 (m, 2 H); 5.60-5.7 (m, 1 H); 7.23-7.71 (rn, 13 H). ‘3C
NMR6 27.9; 30.4; 43.9; 57.3; 60.9; 62.9; 73.1; 81.1; 173.7.
Major diastereomer (2S,3R)-2.20 (6.7 g, 61%) eluted second: [Œ]20D —227.3° (c 0.01,
CHC13). ‘H NMR 6 1.11 (s, 9H); 1.58-1.66 (m, 1 H); 1.69-1.85 (ni, 2 H); 2.49 (d, J 6.1
Hz, 1H); 3.41 (dd,J= 11.3; 7.1 Hz, Ï H); 3.63 (dd,J= 11.3; 2.8 Hz, 1H); 4.68-4.79 (m,
2 H); 5.35-5.46 (m,1 H); 7.11-7.61 (m,13 H). ‘3C NMR 6 28.0; 33.1; 44.2; 59.3; 64.1;
73.1; 77.4; 8 1.6; 174.5. ESMS mlz 478.0 (M+Na). HPJVIS calcd. for C30H33N03 (M+H)
456.25332, found 456.25338.
(2$,3R)-2- tN-(PhF)Amino]-3-(toluenesulfonyloxynlethyl)-hex-5-enoic Acid tert-Butyl
Ester (2.2 1):
A magnetically stirred solution of (28,3R)-alcohol 2.20 (4.4 1 g, 9.65 rnmol, 100 mol%)
and dry pyridine (9.6 ml) in dry CH2C12 (96 ml) was cooled to O °C, treated with solid
toluenesulfonyl chloride (5.56 g, 28.9 mmol), stined at O C for 2 h and at room
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temperature for 24h, and poured into ice water. The mixture was extracted with ethyl
acetate (3 x 100 ml). The combined organic phase was washed with brine, dried (MgSO4)
and evaporated to a residue that was chromatographed using 5-10% EtOAc in hexanes as
eluant. first to elute was (2S,35)-3-allyl azetidine 2.1 (1.06 g, 38% yield) as a solid: m.p.
112.3-113.3 °C, spectral properties were identical to those reported below. Second to
elute was (2S,3R)-tosylate 2.21 (3.1$ g, 47% yield): a clear ou ta]20D —282.8° (c 0.01,
CHC13). ‘H NMR 8 1.13 (s, 9 H); 1.65 (s, 1 H); 1.95 (dd, J= 5.5; 4.7 Hz, 2 H); 2.33 (s, 3
H); 2.52 (s, 1 H); 3.87-3.92 (m, 2 H); 4.71 (d, J= 12.8 Hz, 2H); 5.10-5.30 (m, 1 H); 7.05-
7.67 (rn, 17H). ‘3C NMR 6 21.7; 27.9; 31.5; 43.6; 55.2; 70.5; 73.0; 81.5; 173.3.
(2S,3S)-2-[N-(PhF)Amfno]-3-(toluenesulfonyloxymethyl)-hex-5-enoic Acid tert-Butyl
Ester (2.2 1):
(2S,3S)-Tosylate was synthesized from (2S,3S)-alcohol 2.20 (222 mg, 0.486 rnrnol, 100
mol%) using the sarne procedure as that described above The residue was
chromatographed with 5-10% EtOAc in hexanes as eluant. f irst to elute was (2S,3R)-3-
allyl-1-(PhF)-azetidine-2-carboxylic acid tert-butyl ester 2.1 (45 mg, 21%) as white
crystals: m.p. 128.5-129.5 °C, spectral properties were identical to those reported below.
Second to elute was (28,3S)-tosylate 2.21 (197 mg, 66% yield): a clear ou [Œ]20 —146.4°
(c 0.01, CHC13). ‘H NMR 6 1.25 (s, 9 H); 1.83 (s, 1 H); 2.11-2.14 (rn, 2 H); 2.51(s, 3 H);
2.63 (s, 1 H); 3.22 (s, 1 H); 4.02-4.11 (rn, 2H); 4.88 (d, J= 13.2 Hz, 2H); 5.34-5.40 (rn,
1 H); 7.22-7.84 (m, 17 H). ‘3C NMR 21.6; 27.8; 31.5; 43.6; 55.1; 70.4; 73.0; $1,4; 173.2.
ESMS m/z 6 10.4 (M+H).
(2S,3S)-3-Allyl-1-(PhF)-azetidine-2-carboxylic Acid tert-Butyl Ester (2.1):
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A vigorously stirred mixture of (2S,3R)-tosylate 2.21 (698 mg, 1.14 mmol, 100 mol%)
and powdered Cs2CO3 (560 mg, 1.71 rnmol, 150 mol%) in 10 ml of acetonitrile was
heated at reflux under argon for 19 h, cooled and evaporated to a residue, which was
poured into ice water (15 ml) and extracted with EtOAc (3 x 20 ml). The combined
organic phases were washed with brine, dried (MgSO4) and evaporated to a foam.
Chromatography using 3-5% EtOAc in hexanes as eluent provided (2S,35-3-a11y1-1-
(PhF)-azetidine-2-carboxylic acid tert-butyl ester 2.1 (340 mg, 68 % yield) as white
crystals: m.p. 112.3-113.3 °C. [a]20D 95.1° (c 0.01, CHCI3). ‘H NMR ô 1.25 (s, 9 H);
1.92-2.00 (m, 2H); 2.54-2.62 (m,1 H); 2.99 (t, J= 7.3 Hz, 1 H); 3.13 (d, J= 7.0 Hz, 1
H); 3.58 (t, J= 7.3 Hz, 1 H); 4.89 (d, J= 14.7 Hz, 2H); 5.50-5.60 (m, 1 H); 7,22-7.80
(m, 13 H). ‘3c NMR ô 27.8; 33.9; 36.9; 52.3; 66.1; 76.1; 79.8; 171.7. HRMS calcd. For
c30H31No2 (M+Na) 460.22470 found 460.225 82.
(2S,3R)-3-Allyl-1-(PhF)-azetidine-2-carboxylic Aciil tert-Butyl Ester (2.1):
(2S,3R)-Azetidine 2.1 was synthesized from (2S,35)-tosylate 2.21 (214 mg, 100 mmol)
using the same procedure as that described above to provide (23,3R)-3-allyl-1-(PhF)-
azetidine-2-carboxylic acid tert-butyl ester 2.1 (80 mg, 52% yield) as white crystals: m.p.
128.5-129.5 °c; [a]200 127.6° (c 0.01, cHcl3); 1H NMR ô 1.21 (s, 9 H); 2.18-2.26 (rn, 1
H); 2.32-2.40 (rn, 1 H); 2.47-2.55 (m, 1 H); 3.24 (dd, J= 7.5; 3.7 Hz, 1 H), 3.38 (d, J
9.2 Hz, 1 H); 3.50 (t, J= 8.7 Hz, 1 H); 4.95-5.02 (m, 2 H); 5.61-5.71 (m, 1 H); 7.14-7.76
(m, 13H). 13cNMRô28.1; 30.6; 34.1; 51.0; 61.6; 76.0; 80.3; 170.2.
(2S,38)-3-Propyl-azetidine-2-carboxylic Acid tert-Butyl Ester Hydrochioride (2.22):
A solution of(2S,3S)-2.1 (110 mg, 0.25 mrnol, 100 mol%) in 10 ml ofEtOH : HOAc (9
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1) was transferred into a hydrogenation apparatus and treated with palladium-on-carbon
(20 mg, 10 wt %). The pressure bottie was fihled, vented, and refihled four times with 6
atrn of H2. The reaction mixture was stirred overnight (24 h), filtered onto a plug of
Ce1ite’ 521 (Aldrich USA), and washed thoroughly with EtOH. The filtrate was treated
with 5 drops of iN HC1 and the volatiles were evaporated to give a crude residue of 2.22
(50 mg) as the hydrochloride salt that was used directly for the Fmoc protection: 1H NMR
(CD3OD, 400 MHz) 6 0.85 (t, J= 7.3 Hz, 3 H); 1.14-1.29 (m, 2 H); 1.45 (s, 9 H);
1.49-1.63 (m, 2H), 3.06-3.11 (rn, 1 H), 3.48-3.58 (rn, 1 H), 4.02 (dd,J 19.7; 9.2
Hz, 1 H); 4.85 (d, J 9.6 Hz, 1 H). 13C NMR 613.6; 19.6; 28.0; 35.1; 37.1; 48.7;
62.9; $4.6; 166.7. ESMS rn/z 200.0 (M+H).
Typical procedure for Fmoc protection of azetidïne derivatives. (2S,3S)-3-Propyl-1-
(Fmoc)-azetidine-2-carboxylic Acid tert-Butyl Ester (2.2):
Amine 2.22 (50 mg, 0.25 rnrnol, 100 rnol% from above) in 1 ml of acetone/H20 (2 : 1)
was treated with FmocOSu (101.69, 0.30 mrnol, 120 mol%) and NaHCO3 (25.2, 0.30
rnmol, 120 mol ¾), stirred ovemight, treated with an additional 120 mol% ofNaHCO3,
stirred overnight and evaporated to a reduced solution that was diluted with water and
washed with Et20 (4 x 2 ml). The aqueous phase was acidified to pH = 3 and extracted
with EtOAc (3 x 3 ml). The combined organic phases were washed with brine, dried and
evaporated to a residue that was purified by chromatography using 3-7% EtOAc in
hexanes as eluant. Evaporation of the collected fractions gave 2.2 (51.9 mg, 58% yield)
as a foam: ta]20D—58.6 ° (c 0.01, CHC13). ‘H NMR 6 0.85 (t, J= 2.8 Hz, 3H); 1.18-1.22
(rn, 2 H); 1.43 (s, 9 H); 1.46-1.52 (m, 1 H); 2.81-2.87 (ni, 1 H); 3.72 (bm, 1 H); 3.67-4.31
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(rn, 5 H); 4.62 (s, 1 H); 7.2 1-7.69 (m, $ H); ‘3C NMR ô 13.9; 20.2; 28.1; 3 1.7; 32.9;
47.3; 53.4; 54.1; 67.3; 82.2; 120.0; 125.3; 127.1; 127.7; 141.3; 144.2; 156.0; 168.7.
ESMS mlz 444.1 (M+Na). HRMS calcd. for C26H31N04 (M+H) 422.23258, found
422.23242.
(2S,3S)-3-(3-Hydroxypropyl)-1-(PhF)-azetidine-2-carboxylic Acid tert-Butyl Ester
(2.23):
Borane methyl sulfide complex (25.98 mg, 0.342 mmol, 300 rnol%) was added to a
solution of 3-allyl-azetidine 2.1 (50 mg, 0.114 mrnol, 100 mol %) in anhydrous THF (1
ml) at 00 C under argon, stined for 3 h and treated dropwise with 3N NaOH (0.342 ml,
900 mol %) which resulted in a vigorous evolution of gas. Hydrogen peroxide (35%
aqueous, 0.119 ml, 900 mol %) was added to the mixture, which was stirred for 2 h,
poured into water (12 ml) and extracted with EtOAc (4 xlO ml). The cornbined organic
phases were dried, filtered, and concentrated in vacuo to a residue that was
chromatographed using CHC13:CH3OH 97:3 as eluant to provide primary alcohol 2.23
(48.5 mg, 93% yield) as a light white solid: m.p. 214.6-215.6 °C. [Œ]20D 88.0 (C 0.01,
CHCI3:MeOH, 3:1). 1H NMR (CDC13:CD3OD, 3:1, 400 MHz) 5 1.09-1.24 (m, 13 H);
2.32 (dd, J= 14.0; 7.0 Hz, 1 H); 2.90 (t, J= 6.9 Hz, 2 H); 3.32-3.36 (m, 2 H); 3.47 (t, J=
7.2 Hz,1 H); 7.10-7.70 (m, 13 H). 13C NMR (CDC13:CD3OD, 3:1, 400 MHz) ô 27.4;
29.0; 29.4; 34.8; 52.6; 61.4; 66.4; 76.0; 80.3; 172.7. ESMS rn/z 456.1 (M+H). HRMS
calcd. For C30H33N03 (M+H) 456.25332, found 456.25396.
(2S,35)-3-(-3-tert-Butyldimethylsilanyloxypropyl)-1-(PliF)-azetidine-2-carboxylic
Acid tert-Butyl Ester (2.24):
Chapter 2 65
A solution ofalcohol 2.23 (500 mg, 1.09 mrnol, 100 rnol%) in 100 ml ofCH2C12 at room
temperature was treated with TBDMSC1 (496 mg, 3.29 rnrnol, 300 mol%), DMAP (4 mol
%) and triethylamine (444 mg, 4.39 rnrnol, 400 mol %) and stirred for 24 h. The residue
was dissolved in EtOAc and washed with 1M KH2PO4 (50 ml). The aqueous phase was
extracted with EtOAc (2 x 40 ml). The combined organic phases were dried and
evaporated to a crude residue of 2.24 (600 mg) that was used directly in the next step.
ESMS rn/z 570.2 (M+H).
(2S,3S)-3-(3-Hydroxypropyl)-azetïdine-2-carboxylic Acid tert-Butyl Ester (2.25):
A hydrogenation vessel containing a solution of silanyloxypropyl azetidine 2.24 (120
mg, 0.21 mmol, 100 mol% from above) in 20 ml of MeOH:AcOH (9:1) was charged
with 12 mg of palladium-on-carbon (10 wt %) and stined for 24 h under $ atrn of
hydrogen. The reaction mixture was filtercd through CeliteTM and washed with EtOAc
(30 ml) and MeOH (20m1). The filtrate was evaporated to dryness. The residue was
triturated with hexane (3 x 10 ml). The remaining solid was used without additional
purification. ‘H NMR of crude 2.25: ô 1.44 (s, 9 H); 1.45-1.61 (m, 2 H); 1.74-1.82 (m, 2
H); 2.81 (dd, J’ 15.3; 7.7 Hz, 1 H); 3.57 (m, 3 H); 3.87 (t, J= 8.8 Hz, I H); 4.33 (d, J
7.0 Hz, 1 H). ‘3C NMR ô 28.0; 29.5, 30.0, 30.9, 48.9, 61.8, 63.2, 83.4, 169.3; ESMS rn/z
2 16.0 (M+H).
(2S,35)-3-(3-llydroxypropyl)-1-Fmoc-azetidine-2-carboxylic Acid tert-Butyl Ester
(2.26):
(2S,3S)-1-Fmoc-3-(3-Hydroxypropyl)-Aze 2.26 (120 mg, 66% yield from 2.23) was
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synthesized from crude (2$,33)-3-(3-hydroxypropyl)-Aze 2.25 (90 mg, 0.41$ mmol)
using the general Fmoc protection protocol described above: ‘H NMR 3 1.44 (s, 9 H);
1.50-1.66 (m, 2 H), 1.73 (dd, J= 14.7; 7.4 Hz, 2 H); 2.10 (s,1 H); 3.54 (dd, J= 8.0; 4.1
Hz, 1 H); 3.62 (t, J= 6.1 Hz, 2 H); 4.05-4.35 (m, 6 H); 7.25-7.73 (m, $ H). ‘3C NMR ô
14.2; 28.0; 28.2; 29.6; 30.3; 35.0; 47.2; 62.0; 67.3; $1.9; 119.9; 125.2; 127.1; 127.7;
141.3; 144.0; 156.1; 170.0. ESMS m/z 437.9 (M).
(2$,3S)-3-(3-Methanesulfonyloxypropyl)-1 -Fmoc-azetidine-2-carboxylic Acid tert
Butyl Ester (2.27):
A solution ofalcohol 2.26 (61 mg, 0.133 mmol, 100 mol %) in 11 ml of CH2CÏ2 at O °C
was treated with DMAP (1.63 mg, 10 mol%), Et3N (0.055 ml, 0.399 mmol, 300 mol%)
and methanesulfonyl chloride (0.041 ml, 0.532 mrnol, 400 mol %). The ice bath was
rernoved and the mixture was stirred for 5h at room temperature when TLC showed no
rernaining starting material (Rf = 0.19, 30% EtOAc in hexanes). The mixture was
partitioned between EtOAc (45 ml) and water (15 ml). The organic layer was washed
with 2N HC1 (10 ml), 5% NaHCO3 (10 ml) and water, dried and evaporated to a residue
that was purified by chromatography using 30-35% EtOAc in hexanes as eluant.
Evaporation of the collected fractions provide an ou (57 mg, 80 ¾ yield) of 2.27: ‘H
NMR ô 1.42 (s, 9 H); 1.782-1.88 (m, 4 H); 2.48-2.52 (m, 1 H); 3.02 (dd, J= 8.0; 2.7 Hz,
3 H), 3.57 (dd, J= 8.0; 2.7 Hz, 1 H); 4.08-4.37 (m, 7 H); 7.28-7.76 (rn, 8 H). ‘3C NMR ô
14.3; 26.5; 28.1; 28.2; 29.9; 34.6; 37.5; 47.3; 67.3; 69.0; 82.1; 120.0; 125.3; 127.1; 127.8;
141.3; 143.9; 156.1; 169.7. ESMS rn/z 538.1 (M+Na).
(2S,3S)-3-(3-Azidopropyl)-1-Fmoc-azetidine-2-carboxylic Acid tert-Butyl Ester (2.3):
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Methansulfonate 2.27 (42 mg, 0.0$ mrnol, 100 i;o1%) was dissolved in DMF (5 ml), and
treated with NaN3 (26.32 mg, 0.405 mmol, 500 moÏ%), stirred at 80CC for 8h, cooled and
partitioned between EtOAc (12 ml) and water (6 ml). The organic layer was washed with
2N HC1 (5 ml), 5 % NaHCO3 (5 ml) and water (5 ml), dried and evaporated. The residue
was chromatographed using 3-5% EtOAc in hexanes as eluant. Evaporation of the
collected fractions gave azide 2.3 as white foam (23 mg, 62% yield): IR crn1 2098.44. ‘H
NMR 31.30 (s, 9 H); 1.46-1.64 (m, 5 H); 2.50-2.60 (m, 2 H); 2.74 (dd, J = 11.7; 6.8 Hz,
1 H); 2.96 (dd, J = 11.6; 7.6 Hz, 1 H), 3.22 (dd, J = 12.5; 6.3 Hz, 2 H); 3.52 (t, J= 6.3
Hz,1 H); 3.80 (t, J = 7.1 Hz, 1 H); 7.18-7.68 (rn, 8 H). ‘3C NMR 6 26.5; 28.1; 31.4;
35.0; 46.1; 51.3; 58.5; 63.1; 72.8; 81.1; 119.7; 125.6; 126.8; 127.2; 141.1; 146.2, 171.9.
ESMS m!z 419.1 (M- 43).
(2S,3S)-3-(2-Carboxyethyl)-1-Fmoc-azetidine-2-carboxylic Acid tert-Butyl Ester
(2.4):
A mixture of alcohol 2.26 (0.114 mmol, 100 mol%), TEMPO (1.23 mg), CH3CN (0.57
ml) and sodium phosphate buffer (0.427 ml, 0.67 M, pH = 6.7) was heated to 35 °C,
treated with sodium chlorite (NaCIO2, 6 mg, 80%, 0.228 mmol in 0.114 ml H20), stirred
5 min and treated with dilute bleach (0.0014 ml, 10% NaOCI diluted into 0.057 ml). The
mixture was stirred at 35 °C for 24 h when TLC showed no starting material (Rf = 0.30,
4% MeQH in CHC13). The pH was adjusted to 8.0 with 2.0 N NaOH (0.136 ml). The
reaction was quenched by pouring into cold (0 °C) Na2SO3 solution (0.57 ml, 0.5 M)
maintaining the bath temperature below 20 °C. The pH of the aqueous layer was between
8.5-9.0. After stirring for 0.5 h at room temperature, diethyl ether (2 ml) was added. The
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organic layer was separated and discarded. The aqueous layer was treated with EtOAc (5
ml) and acidified with 2.0 N HC1 (—0.5 ml) to pH 3-4. The organic layer was separated,
washed with water (2 x 5 ml) and brine (1.5 ml), and concentrated to a solid that was
recrystalyzed from EtOAc:petroleum ether (2:10). Dicarboxylate 2.4 (47 mg, 90 % yield)
was isolated as white crystals: m.p. 61.5-62.5 °C. [Œ]20D —56.3e (c 0.0 1, CHC13). ‘H NMR
6 1.48 (s, 9 H); 1.97-2.04 (rn, 2 H); 2.34-2.49 (m, 2 H); 2.50-2.57 (rn, 1 H); 3.53
(dd, J 8.0; 2.6 Hz, 1 H); 4.11-4.21 (rn, 3 H); 4.39 (cl, J= 7.0 Hz, 2 H); 7.28-7.74
(m, $ H). ‘3C NMR 6 28.0; 28.2; 28.7; 31.0; 34.5; 47.3; 52.6; 67.4; 82.2; 120.0; 125.2;
127.1; 127.8; 141.4; 144.0; 156.2; 169.6; 177.8. ESM$ mlz 474.2 (M+Na). HRM$
calcd. For C261129N06 (M+H) 452.20676 found 452.20700.
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CHAPTER 3
Synthesis of 2,4-substituteil azetidin-3-ones and
4-substïtuted azetidine 2-carboxylic acids
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3.1 Introduction:
Azabicyclo[X.Y.O]alkane arnino acids are constrained dipeptide mimics that can serve as
conformationally fixed surrogates of peptide turn secondary stnicrtures.”2 In these
bicyclic structures, three dihedral angles (w, i’ and ) are restricted (f igure 3.1).
Incorporating these constrained scaffolds into peptides can give useful information about
the bioactive conformation of the parent peptides. Enhanced activity and metabolic
stability have also resulted upon incorporation of azabicyclo[X.Y.O]alkane amino acids.”2
figure 3.1: Dihedral angles constrained by an azabicyclo[X.Y.O]alkane arnino acid in a
peptide.
As components of fl-lactams, fused azetidines represent one of the most important classes
of antibiotics, and a large number of 3-1actarn-derivatives have been synthesized and
tested for biological activity.3 Due to increasing resistance of bacteria to popularly used
antibiotics (e.g. penicillin), there is a need for new medications that show antibiotic
activity. One approach is to use 3-lactam derivatives which cannot be metabolized by the
bacteria. In this respect, molecular modeling studies have proposed that the hybridization
characteristics of the nitrogen in bicyclic azetidines such as fused y-lactarn-azetidine
analogues can approximate the pyramidal distortions of the nitrogen atom obseiwed in
R2
m
o
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penicillin.4 Azetidin-3 -ones are non-hydrolyzable 3-1actam isosteres which cannot be
rnetabolized by bacteria and they are stable to lactam cleaving enzymes.5
To the best of our knowledge only a few synthetic routes to azetidin-3-ones have been
published. The intrarnolecular carbene-insertion reaction was studied by Rapoport and
co-workers using 4-arnino-2-diazo-3-oxobutanoates 3.1 (Scheme 3.1, a).6 Alternatively,
ring closure was also achieved using 1-amino-3-bromopropan-2-one 3.3 in an
intrarnolecular dispiacement in the presence ofNaHCO3 (Scheme 3.1, b).7 Azetidin-3-ol
3.7 was synthesized using 1,3-dihalopropan-2-ol 3.6 and toluene-4-sulfonarnide in 50-
68% yield. Deprotection and oxidation of silylether 3.7 using Cr03 provided the
conesponding azetidin-3-ones 3.8 (Scherne 3.1, c).8 Using arnino acids as starting
materials, a series of 2-substituted azetidin-3-ones 3.10 have been synthesized by
application ofmetal carbenoid insertion reactions of diazoketones 3.9 (Scherne 3.1, d).
a) C02Me Rh2(0Ac)4
0C02Me
,NH N2 N,
R 3.1 32R
b) MeR
3
MeN,
NaBH4
e Me
3.3 3.4 3.5
1) HOAc
TBDMSO TsNH2, 1<2003 TBDMSO 2) Cr03 O
c) X’X NTs
H-N2 Rh2(OAc)4
d H R= Me, PG= BocPG—N0 R= i-Pr, PG= Z
R= PhCH2000NH( 0H2)4, PC =Z
R R R= PhCH2OCOCH2, PG= Soc
3.9 3.10
Scherne 3.1: Reported synthesis ofazetidin-3-ones
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acid 3.12 and azabicyclo [5.2.0] aikane arnino acid 3.13 (Figure 3.3). These fused
azetidines are dipeptide surrogates that offer potential for developing new antibiotics.
PHNCO2H PHNCO2H
azabicyclo [4.2.0]alkane azabicyclo [5.2.0] alkane
amino acid 3.12 amino acid 3.13
P= protecting group
Figure 3.3: Fused azetidine targets
3.2 RESULTS AND DISCUSSION
3.2.1 Study of the synthesis of 4-substituted azetidine-3-ones by
carbenoid insertion into the ‘y-amino N-H bond of c-diazo f3-diketone
and $-ketoester substrates.
Metal carbene chernistry has been widely used as an efficient tool in organic chernistry.
Although the rhodium catalyzed N-H insertion reactions of diazoketones have been
frequently ernployed in heterocycle synthesis,” few examples of this intrarnolecular
cyclization have been reported for forrning azetidin-3-one rings. 6,11-14 For example, 2-
carboxy-3-oxo azetidine 3.2 was prepared from glycine; however, its isolation by colurnn
chromatography using methanol in the eluent led to acid catalyzed ring opening and
formation of diester 3.14 (Scheme 3.2).
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1.zcl o
2.CDImethyl _Jt ,CO2CH3 cc CH
glycine malonate dianion HZ 2
Rh2(OAc)4 2 3 CH3OH/CHCI3
3.p-(carboxyphenyl) Si02 O O
sulphonyl azide 3.1 3.2 3.14
Scherne 3.2: Synthesis of2-carboxy-3-oxoazetidine 3.2 from a-diazo 43-ketoester. 6
2-Substituted azetidin-3-ones have been synthesized and used in the total synthesis of
racemic trans-polyoxirnic acid from N-Boc glycine as starting material by application of
the carbenoid insertion to N-H bond methodology 12
N2
/. OH ï. CO(lm)2, Mg(OEt)2 II Rh2fOAc)4, v0BocHN f tert-butyl malonate, 82% BocHN CO2tBu CH2CI2, 38% j
U. HOOCfC6H4)S02N3, 96% o( NBoc
3.15 3.16
3.17
CO2H
NH
± Polyoximic Acid
Scherne 3.3: Synthesis ofracernic polyoxirnic acid using 2-substituted azetidinone 3.17.12
a-Amino acids provided an excellent starting point for the synthesis of 2-substituted
azetidine-3-ones 3.20 in enantiopure form. Application of serine in this method
developed by Hanessian and co-workers lcd to the synthesis ofpolyoximic acid. 9,13
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t-BuOCOCI, NMM,
CH2N2 Et20, CH2C12,
HO_CH2R to 0°C
________
NHPG 1) Pci5, Et20
3.18 2) CH2N2, 0°C
tîC02H
trans-Polyoximic Acid cis-Poiyoximic Acid
Scheme 3.4: Synthesis of enantiopure azetidin-3-one 3.20 from
31812,13
Imidazole, TBDPSCI
HOOH
N H Boc
N-Bac-L-serine
catyst, CH2C12
o TBDPSO N
Boc
1. C1CO2Et, Et3N ,THF
0 2. diazobutane in Et20,
TBDPS0(0H o°c ta rt
NHBoc 50-55% from L-serine
Scheme 3.5: Synthesis of2,4-dialkyl azetidine-3-one 3.23. 14
With this precedent in hand, carbenoid insertion into the 7-arnino N-H bond was pursued
using diazo f3-diketone and Œ-diazo 3-ketoester substrates.
N2CHR Rh2(OAc)4
cH2Cl2 L_NPG
NHPG temprature
3.19 3.20
R OTBDMS, PG Cbz, yield: 19%
R= OTBDPS, PG Bac, yield: 50%
R= Ph, PG Cbz, yield: 71%
R= H, PG= Cbz ,yield: 68%
R= H, PG= Bac, yield: 0%
N-protected D-serine
Sirnilarly, 2,4-diaikyl azetidin-3-one 3.23 has been synthesized from Boc-L-serine in
35% yield. The key step was based on a rhodium carbenoid N-H insertion ofa’-dialkyl-a
diazoketone 3.22 (Scheme 3•5)14
3.21
TBDPS0j
NH N2
Boc
3.22
3.23
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3.2.1.1 Attempted syntliesïs of4-substïtuted azetidine-3-one 3.30 via diazo insertion:
As rnentioned previously, 2,4-disubstituted azetidin-3-one 3.23 was synthesized from the
acylation of diazobutane with the mixed anhydride derived from protected L-serine 3.21
followed by metal carbenoid N-H insertion (Scheme 3•3)•14 Inspired by this resuit, we
conceived the synthesis of 4-substituted azetidine-3-one 3.30 from the corresponding
symmetric a-diazo dione 3.29.
First, N-Boc-L-serine O-tert-butyldiphenylsilylether 3.27 was prepared from L-serine as
previously reported.”2 Acylation of L-serine with (Boc)20 and Na2CO3 in 1:2
water:dioxane, followed by treatment with TBDPSC1 in the presence of imidazole in
DMF gave serine derivative 3.27 in 96% yield. Carboxylic acid 3.27 was activated with
isobutylchloroforrnate and N-rnethylrnorpholine (NMM) in dichiorornethane and then
reacted with an ethereal solution of diazomethane to provide a-diazoketones 3.28. This
diazoketone was purified by colunrn chromatography and exhibited NMR and IR spectra
that were consistent with the literature.’3 Attempts for the synthesis of a-diazo dione 3.29
by acylation of Œ-diazoketone 3.28 with the mixed anhydride derived from protected
serine 3.27 using various bases (n-BuLi and diisopropylarnine, Et3N, NMM) in different
solvents (THF, CH2C12) at different temperatures (rt, -20, -40, -78, -90 °C) did flot meet
with success and lcd to cornplicated mixtures which consisted of several products
(Scherne 3.6).
In an earlier attempt, N-Boc-L-serine O-tert-butyldimethylsilylether 3.26 was prepared;
however, as noted in the literature,’3 the TBDMS analogs were less stable than their
TBDP$ counterparts. For example, activation of acid 3.26 folÏowed by acylation of
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diazomethane and chrornatography over silica gel (Scherne 3.6) lcd to the formation of
multiple unidentffied materials.
TBDMSCI,Et3N,
DMAP,
HONCO2H Na2CO3 HONCO2H CH2CI2, RONCO2H
tJH2 (Boc)20, 97% HBoc TBDPSCI, Imidazo, HBoc
3.24 3.25 DMF, 96% 3.26, R= TBDMS
3.27, R= TBDPS
1. isobutylchloroformate, RON2
1. base
ROjOR
NMM, CH2CI2 2. 3.27, iso6utylchloroformate,
NHBoc NMM, CH2CI2 ‘JH N2 HN
2. CH2N2, 95% 3.28, R= TBDPS Boc Bac
3.29, R= TBDPS
BocHN OR
3.30
Scheme 3.6: Attempted synthesis of 4-substituted 3 -azetidinone 3.30.
3.2.1.2 Attempted synthesis of 4-substituted azetidine-3-one 3.34 via diazo insertion
using ethyldiazoacetate:
In another effort, N-Boc-serine-O-silylether 3.27 was reacted with ethylchloroformate
and a tertiary amine to afford a rnixed anhydride intermediate 3.3 1, which was directly
reacted with ethyl diazoacetate. After purification by colurnn chrornatography, this
reaction led to the formation of a side product that was studied by spectroscopic methods:
1H NMR indicated 39 protons, LC/MS analysis indicated for C28H40NO6Si (M+H)
rn/e:514.1, and in the IR spectrum, no signal in the desired region for N=N functional
group was observed. Based on this evidence, the desired compound 3.32 was presumed to
have lost N2 during purification by column chrornatography, and fl-keto ester 3.33 was
forrned (Scherne 3.7).
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In another attempt, the residue was directly used without purification (crude 3.32) for the
cyclizations step using Rh2(OAC)4 in CH2CI2 but according to TLC and LC/MS analyses,
several unidentified cornpounds were produced (Scherne 3.7).
o oNEt3, CICO2Et
TBDPSONCO2H ethyldiazo9cetate
1HBoc
CH2CI2
FJHBoc TBDPSO‘ 0Et
3.27 3.31,confirmed by LC/MS NHBo2
3.32
Rh2fOAc)4 ,/
CH2CI2/
TBDPSO o o o
TBDPSOOEt
CO2Et E
NHBoc
3.34 3.33
MWfor (C28H39NO6Si): 513.1
Scherne 3.7: Atternpted synthesis ofN-Boc 2,4-disubstituted azetidinone 3.34.
In the light of the problems associated with the synthesis of a-diazo compounds 3.29 and
3.32 and their subsequent ring annulations, we began to study of an alternative approach
to provide Œ-diazo keto compounds such as 3.40 for the synthesis of desired 3-
azetidinone.
3.2.1.3 Synthesis of 4-substituted azetidine-3-one 3.43 by metal carbenoid N-H
insertion on y-amino f3-ketophosphonate 3.39:
Intramolecular N-H insertion reactions have yielded 5-substituted pyrrolidine 2-
phosphonate 3.37 from a-diazo 3-keto phosphonate 3.36 (Scherne 3.8). 15
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o
Q
N3—S--K.j—NH 4moI% Rh2(OAc)4
O (4-ABSA) DCM, 35°C
Boc.. NaH, THF, 83-91% Boc.. 65-88% F )._QNH O O NH O O
-. P(OMe)R
oc
2
N2 3.37, R Ph, CH2=CH,
3.36 Me, n-Bu, t-Bu
Scheme 3.8: Synthesis of 3-oxo pyrrolidine phosphonate 3.37 from 6-arnino a-diazo 3-
ketophosphonate 3.36.
Inspired by this example for making 2,5-disubstituted pynolidines, we investigated a
complimentary route to make 2,4-disubstituted azetidines. fl-Keto a-diazo phosphonate
3.40 was derived fiorn protected L-serine 3.3$. Esterification of N-(Boc)-serine-O-tert
butyldiphenyl silyl ether 3.27 with methyl iodide and sodium bicarbonate in DMF gave
L-serine methyl ester 3.38 in 91% yield after chromatography. 3-Ketophosphonate 3.39
was synthesized from methyl ester 3.3$ by acylation of the lithium anion of dimethyl
methyl phosphonate, produced with n-BuLi in THF. The diazo transfer to 3-
ketophosphonate 3.39 was accomplished using 4-acetamido benzene sulfonyl azide (4-
ABSA) and sodium hydride as a base in THF to furnish a-diazo t3-ketophosphonate 3.40
in 72% yield. Diazo derivative 3.40 was heated at reflux with Rh2(OAc)4 in CH2C12 to
provide N-Boc azetidine-2-dimethoxy phosphonate 3.41. Atternpts to purify 3.41 by
column chromatography were unsuccessftd and the product decornposed; however,
azetidine 2-phosphonate 3.41 could be directly condensed with aldehyde 3.42 in a Wittig
reaction using DBU in THF to provide azetidine 3.43 in 31% yield from 3.22 (Scheme
3.9) as a mixture of two cis / trans olefin isomers (according LC/MS) in a 3:1 ratio as
assessed by measurement of the triplet signais at 6 4.78 and 4.73 ppm in the ‘H NMR
spectrum. The structure of 2,4-disubstituted 3.43 has been characterized by ‘3C NMR, ‘H
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NMR and HRMS analyses. The ‘3C NMR spectrum showed three carbonyl groups, with
a signal for ketone at 6 190.5 pprn, along with the carbonyl of Boc group at 6 152.3 pprn
and carbonyl of the t-butylester at 6 174.6 ppm. The formation of a double bond was
confirmed by 1H NMR which showed the presence ofthe vinyl proton at 6 5.58 pprn for
the major olefin isorner. Further structural confirmation of 3.43 was accornplished by
HRMS calculated for C52H59N2O6Si (M+H) 835.41369, indicated the mass of
835.41484.
TBDPSO(CO2H NaHCO3, CH TBDPS0_ CO2Me__CH3PfO)(OMe)2
TBDPS0(’QMe
NHBoc DMF,91% NHB0c n-BuLi-78°C,75% NHBoc
3.27 3.38
3.39
o
o
— —CH3 O
N3—NH
Rh2(OAC)4 TBDPSO0
NaH, THF, 72% NHBOC CH2CI2 BocJ—Ç 7,0
P\3.40 MeC OMe
H—CO2tBu 3.41
O NHPhF
3.24 TBDPS0\,2°
DBU,THF,31% Boc—
C0tBu
3.43 PhFHN
Scherne 3.9: Synthesis of 2,4-substituted azetidinone 3.43 via 3-ketophosphonate 3.39.
Elaboration of 3.43 toward the bicyclic azetidine analogue 3.12 via reduction of the
carbonyl group of azetidinone 3.43 to the corresponding alcohol using Luche conditions
or NaBH4 or NaCNBH3/HOAc, as well as the reduction of the double bond using PdIC in
MeOH gave only recovered starting material.
In conclusion, 2,4-disubstituted azetidin-3-one 3.43 was synthesized for the first tirne in 7
steps from L-serine via intramolecular metal carbenoid N-H insertion of a-diazo -
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ketophosphonate 3.40. This rnethod for the synthesis of substituted azetidin-3-ones may
be useful for the preparation of other azetidine heterocycles.
3.2.2 Synthesis of 4-substituteil Aze analogues by intramolecular SN2’
reaction:
Although intrarnolecular rhodium catalyzed insertion of diazo ketones into N-H bonds
did provide 4-substituted azetidine 3.43, the development of more efficient rnethodology
for making these challenging heterocycles was pursued and an alternative strategy was
expÏored.
3.2.2.1 Synthesis of 4-propenyl Aze 3.4$ from allylic alcohol 3.46 by
SN2’dïsplacement:
b our knowledge, there was no precedent in the literature of using intramolecular
cyclization via SN2’ reaction to form an azetidine ring, hence, a methodological study was
carried out at first on simpler models to explore the appropriate conditions.
Allylic tosylate 3.47 was prepared as a mode! for exploring the SN2’ reaction. Treatrnent
of ethyl acetate with the lithium anion of dirncthylmethylphosphonate in THF, afforded
Œ-keto phosphonate 3.44 after distillation (bp 76-79 °C/3 mmHg) in 82% yield. Aspartate
f3-aldehyde 3.42 was treated with 3.44 in the presence of Cs2CO3 in CH3CN to provide
13,y-unsaturated ketone 3.45 in 67% yield. Reduction of ketone 3.45 with CeC13.7H20 and
NaBH4 in MeOH produced allylic alcohol 3.46 as a mixture oftwo diastereorners in a 4:1
ratio (confirmed by LC/MS) after purification by column chromatography. Activation of
alcoho! 3.46 to the corresponding tosylate 3.47 was performed using
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toluenesulfonylchloride and pyridine in CH2C12. The products were purified by colurnn
chrornatography using a gradient eluent of 3-10% EtOAc in hexanes and gave three
fractions. The first fraction was an inseparable mixture of diastereomers and olefrn
isorners of azetidine 3.4$ in 11% yield, and the second fraction was tosylate 3.47 in 35%
yield as an inseparable mixture of diastereomers and olefm isorners. Also, alcohol 3.46
was recovered as third fraction in 28% yield after chromatography (Scheme 3.10).
Attempts to prepare azetidine 3.4$ from tosylate 3.47 using different bases (Cs2CO3,
K2C03, Et3N) in different solvents (CH3CN, DMF, THF) were unsuccessful and starting
material was recovered.
H—CO2tBu
O o ONHPhF ° /
u n-BuL1, THF ?
—OM 3.42
CO2tBu
CH3 OEt H3CjoMe
82% CH3- DMe
e
Cs2CO3, CH3CN, OH3 FPhHN
3.44 67% 3.45
NaBH4,MeOH, CHHN2
TSCI,pyridine
TSOco2tBu
+ 3.46, 28%
81% CH3 FPhHN PhFN CO2tBu
347, 35% 3.48, 11%
Pd/C, H2, 8 atm J_Cs2CO3, CH3CN
MeOH:ACOH
NCO2tBU
349 3.48
Scheme 3.10: Synthesis of4-propenyl Aze 3.4$ from allylic alcohol 3.46.
‘H NMR of azetidine 3.4$, showed a cornplicated spectrum that contained the mixture of
two diastereomers as well as Z and E olefin isorners, which caused difficulties during
spectral assignment.
for further evidence of the formation of propenyl azetidine 3.48, hydrogenation was
perforrned at $ atm using palladium-on-carbon as catalyst in 9:1 MeOH:AcOH. This
caused double bond reduction and cleavage of the phenylfluorenyl group. 4-Propyl
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azetidine 3.49 was purified by HPLC which provided a mixture of two inseparable
diastereomers of 4- propyl Aze 3.49 in a 3:2 ratio as assessed by the measurement ofthe
diastereomeric multiplet signais at 3.51 and 3.33 ppm in the ‘H NMR spectrum. The
exact mass of 4-propyl Aze 3.49 was confirmed by HRMS. (calcd. 200.16451 for
C,,H22N02 (M+H), found 200.16358).
3.2.2.2 Attempted synthesis of 4-substituteil Aze 3.53 from allylic alcohol 3.51 by
SN2’ reactïon:
To further probe the intrarnolecular SN2’ rnethodoiogy, ailylic aicohol 3.51 was prepared
from fl-keto phosphonate 3.39. For the synthesis of 4-substituted Aze 3.53, activation of
alcohol 3.51 foiiowed by cyclizations via SN2’ reaction was examined. The Wittig
reaction of aldehyde 3.42 with serine-derived f3-keto phosphonate 3.39 using Cs2CO3 in
CH3CN gave 3-unsaturated ketone 3.50 (72% yield). Reduction of 3.50 using
CeC13.7H20 and NaBH4 in MeOH gave secondary aicohol 3.51 as a mixture of
diastereomers (78% yieÏd), which were separated by coiumn chrornatography. The
structure of secondary aicohol 3.51 was estabiished by ‘H NMR and ‘3C NMR. The
formation of the E-isomer was confirmed by proton NMR which showed a vicinal
coupiing constant of 15.7 Hz for the vinyi protons. Atternpts to activate alcohol 3.51 as
the corresponding tosyiate and mesylate, using toluenesuifonyl chloride and pyridine as
base in CH2C12 or methanesulfonyi chloride and Et3N as base in CH2C12 respectively,
were however unsuccessful and onÏy starting material was recovered (Scheme 3.11).
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o Q Cs2003, CH3CN, O
R—OMe 72% ,— COtBu CeCI3 .7H20, NaBH4,
TBDPSO OMe H—CO2tBu TBDPSO MeOH, 78%NHBoc O NHPhF NHBoc NHPhF
339 3.42 3.50
TBDPSOCO2tBU
TsCpyndine O TBDPSOCO2tBU
NHB0c NHPhF MsCI, Et3N NHB0c NHPhF
CH2CI2 3.52, R= Ts, Ms
3.51
TBDPSO
tJH PhEN
Boc CO2tBu
3.53
Scheme 3.11: Atternpted synthesis of 4-substituted Aze 3.53 starting from serine
phosphonate 3.3 9.
3.2.2.3 Attempted synthesïs of 4-vinyl Aze 3.59 from allylic alcohol 3.55:
Preparation of 4-substituted Aze 3.59 was examined by the synthesis of allylic mesylate
3.57. Dehydro arnino adipate 3.54 was made as previously described in reference 16.
Reduction of the w-ester of diester 3.54 using DIBAL-H in THF at -40 oc provided the
corresponding alcohol 3.55 in 95% yield, after purification by chrornatography. Attempts
at activation of alcohol 3.55 to the corresponding tosylate using toluene chloride and
pyridine in CH2C12 were, however, unsuccessftd and starting material was recovered
(Scheme 3.12).
O rCO2Me
H Ph3P=CHCO2CH3, DIBAL-H, -40°C
PhFHN CO2tBu THF, A, 93% PhFHN CO2tBu THF, 95% PhFHN
CO2tBu
3.42 354 3.55
TsCIpyridine
CH2CI2 PhFHN CO2tBu
3.56
Scheme 3.12: Atternpted synthesis ofthe tosylate derivative of alcohol 3.55.
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Alcohol 3.55 was thus converted to the corresponding mesylate 3.57 by using
methanesulfonyl chloride with Et3N as base and DMAP as catalyst in dichioromethane
(DCM). Under these conditions, mesylate 3.57 and pipecolate 3.58 were obtained in 43%
and 38% respective yields after separation by column chrornatography. The next issue
was the synthesis of azetidine 3.59. Attempts to prepare azetidine 3.59 from mesylate
3.57 using Cs2CO3 in acetonitrile were unsuccessfiul and starting material was recovered.
Ernploying triethylarnine and HMPA at reflux led to the formation of several unidentffied
cornpounds (Scherne 3.13).
PhFHN
3.55 3.58, 38% 3.57, 43% 359
Scherne 3.13: Synthesis ofpipecolate 3.58 from allyl alcohol 3.55 on route to mesylate
3.57.
The structure ofpipecolate 3.58 was assigned using NMR spectroscopy. In particular, the
‘3C-DEPT spectrum of 3.58 in chlorofonn indicated the presence of two methylene
groups at 8 38.76 and 45.45 pprn, and there was no methylene carbon in the vinyl region
which was consistent with the formation of pipecolate 3.58 instead of azetidine 3.59.
Azetidine 3.59 was not detected in these experirnents. A mechanism for the formation of
pipecolate 3.58 may involve SN2’ like nucleophilic attack of the DMAP to the vinylic
carbon followed by dispiacement of the mesylate group. The intrarnolecular N-alkylation
ofthe conesponding interrnediate via an alternative SN2’ of gave pipecolate 3.85 (Scheme
3.14).
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Co M s
>
Ph F
CO2tBu
ButO2C ButO2C 3.58
Scherne 3.14: Possible rnechanism for the intramolecular N-alkylation leading to
pipecolate 3.58.
3.2.2.4 Synthesis of 4-vinyl Aze 3.65 via SN2’ reaction of allylic chlorïde 3.64:
The SN2’ intrarnolecular N-alkylation to synthesize piperidines, pyrrolidines and 1,3-
disubstituted 1,2,3,4-tetrahydroquinolines, has been perforrned with various reagents and
catalysts, including complexes of Pd(O)’7 and Pd(II),’8 and Ag(I) salts.’9 For example, a
4:1 mixture of cis- and trans-2-carboxy-5-vinylpyrrolidines was synthesized in 77% yield
using Ag(I) to carry out the intrarnolecular SN2’ N-alkylation1° of 2-tert-
butoxycarbonyloxy-7-chlorohept-5-enoic acid methyl ester 3.61 (Scheme 3.15).
allyl chloride, C02Me
Grubbs II, CH2CI2, BuLi, -78°C, AgOTf, Boc
40°C, 67%
-
jj THF, 77% (2S,5R) 3.11
Me0 cK ( ce + (2S,5S):(2S,5R)
NHB0c NHBoc
3.60 3.61
Boc
f2S,5S)
Scheme 3.15: Synthesis of 2—carboxy-5-vinylpyrrolidine 3.11 using AgOTf in SN2’
alkylation.1°
The extension of this methodology was thus pursued for the synthesis of 4-vinyl Aze. N
(Boc)alÏylglycine 3.62 was prepared according to the literature protocol,20”9 and
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esterified with CH3I and sodium bicarbonate in DMF to afford methyl allylglycinate 3.63
as a clear ou in 87% yield ($cheme 3.16).
8 steps CH3I, NaHCO3 allyl chloride,
D-Asp
ref.24 BocHNCO2H DMF, 87% BOCHNCO2Me
3.62 3.63 BocHN
CO2Me
n-BuLi, AgOTf — 3.64
THF, -78 O 25%
CO2Me
3.65
Scherne 3.16: Synthesis ofvinyl azetidine 3.65.
for the synthesis of azetidine 3.65, ouf next objective was the introduction of the
appropriate leaving group and subsequent intrarnolecular N-alkylation. Reaction of olefin
3.63 with a solution of allyl chloride and Gnibbs second generation catalyst in CH2C12
gave allyl chloride 3.64 in 62% yields. Formation of the vinyl azetidine 3.65 occuned in
low yield (25%) on reaction of allyl chloride 3.64 with silver triflate and n-BuLi in THF
(Scherne 3.16). ‘H NMR of vinyl azetidine 3.65 showed the presence of two
diastereorners and two amide rotarners in the vinylic region that caused difficulties during
spectral assignment. ‘H NMR temperature studies ofvinyl azetidine 3.65 in CHC13 at 25
°C in the vinylic region exhibited two trans and two cis protons in a 5.7:1 ratio as
assessed by measurernent of the cis doublet signais at 3 5.38 and 5.18 pprn. Also, ‘H
NMR examination of 3.65 in CHC13 at -55 oc resulted in an increase ofthis ratio to 2.9:1
due to restricted rotation about the Boc group (Figure 3.4). Moreover, it was noted that
the singlet tert-butyl group was particularly broad (6 1.45-1.50 pprn at 25 oc and 1.39-
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1.52 pprn at -55 °C) which suggested the presence of mixtures of diastereorners and
carbarnate cis- and trans-rotamers. The formation of vinyl azetidine 3.65 was confinried
by ‘3C NMR and HRIvIS, in which a 13C NMR study showed the presence of vinylic
methylene groups between 6 113.2-117.3 pprn and HRM$ indicated the mass of
242.10159 for C12H20N04 (M+H).
— R) — R)
S)° +
CH3 CH3 CH3 CH3
trans-(2S,43)-3.65 trans-(2S,4R)-3.65 cis-(234S)-3.65 cis-(2S,4R)-3.65
Figure 3.4: Suggested diastereomers and the carbamate cis and trans-isomers ofN-Boc 4-
vinyl azetidine 2-methyl ester 3.65.
To ftirther characterize azetidine 3.65, attempts were made to remove the Boc group;
however, decomposition of the azetidine ring was observed by both TLC and LC/MS
analysis, when employing protic acids such as TFA in CH2C12, 4M HC1 in dioxane, and
HC1 (g) in CH2C12. When a Lewis acid was ernployed, only starting material was
recovered on treatment of azetidine 3.65 with ZnBr2 in CH2CÏ2 to remove the Boc
group.22 Furthennore, attempts to elaborate 4-vinyl azetidine 3.65 by transformations of
the olefin such as conversion to the corresponding primary alcohol using hydroboration
oxidation, or saturation by hydrogenation using Pd/C in MeOH:HOAc at 4 atm, as well
as the transfer the methyl ester to the corresponding ethyl ester using a solution of sodium
ethoxide 0.04 M in ethanol, ail failed.
In surnmary, a mixture of two diastereomers of 4-vinyi Aze 3.65 was synthesized in 11
steps from aspartic acid by application of allylglycine methyl ester 3.63 in a cross
metathesis / intramolecular SN2’ N-alkylation strategy.
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3.2.3 Attempts to synthesize of 4-substituted Aze 3.71 via
intramolecular nucleophulic ring opening of epoxide 3.70:
Littie is known about the formation of azetidine rings by the nucleophilic ring opening of
epoxides with amine nucleophiles. Although, several (R,5- 1 -alkyl-3 -hydroxy-2-
phenylazetidines 3.67 were synthesized by reaction of (R,R)-2-(1-bromobenzyl) oxirane
3.66 with aliphatic primary amines (Scherne 3.17 a).23 3-Hydroxy azetidine 3.69 bas also
been made by an exo-tet type cyclization and double inversion in two sequential SN2
reactions on epoxyarnine 3.6$ (Scheme 3.17 b). 24
Br Ph OH
2 R= n-Pr, allyl, i-Pr, t-Bu, PhCH2,
a) Ph RN p-CI-C6H4CH2, PhCH2CH3,
3.66 3.67 C16H33, CH2002Et
R’
MgBr2 Br 4-exo-tet ring closureb)
R1NHR’ RNHR’ -MgBr2
3.68 8MgBr OH
3.69
Scheme 3.17: Synthesis ofazetidine ring from epoxide.
High ring strain makes epoxides reactive to nucleophilic attack.25’26 We envisioned that a
method based on intramolecular ring opening of the epoxide by an amine or amide could
be used to prepare 4-substituted Aze. The synthesis of epoxide 3.70 and 3.74 from L
aspartic acid was thus explored in another attempt at azetidine ring formation.
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3.2.3.1 Synthesis of epoxide 3.70 from L-aspartic acid:
Methyl aiiylgiycinate 3.63 was synthesized as described in section 2.2.3 and reacted with
rneta-chloroperbenzoic acid (mCPBA) in CH2CI2 to give epoxides 3.70 as a 4: 1 mixture
of two diastereorners (according to LC!MS) in 72% yield after purification by colurnn
chromatography.
With epoxides 3.70 in hand, we tried different conditions for intrarnolecular nucleophilic
attack using Lewis acids, such as AgOTf, Cul, Cu(OTf)2, and TiC!4, without base or by
ernploying various bases (n-BuLi in THF, NaHMDS or LiHMDS in THF); formation of
azetidine 3.71 was neyer observed, and in ail cases starting material was recovered
according to TLC and LC/MS analysis (Scherne 3.18).
AgOTf, n-BuLi, THF
J mCPBA, CH2CI2 ° Cd Le/is, CH2C12
72% or KHDS, THF
BOCHNCO2Me BocHN CO2Me Ot L1HMDS, THF BOCN_CO2Me
3.71
3.63 3.70
Scherne 3.18: Atternpts to synthesize 4-substituted Aze 3.71 from epoxide 3.70.
3.2.3.2 Synthesis of epoxide 3.74 from L-aspartic acid
The poor reactivity of the Boc protected nitrogen may be due to resonance with the
carbonyl of the carbamate reducing the nucieophilicity of the nitrogen. Repiacernent of
the Boc protecting group with a toluenesuifonamide was examined in order to increase
the nucleophilicity of the nitrogen and favor N-alkyÏation. Deprotection of N-Boc
allyigiycine methyl ester 3.63 using 50:50 TFA/CH2C12 for 20 min provided allyglycine
methyl ester 3.72 in 85% yield. Protection of the nitrogen using p-toluene
suifonylchioride and pyridine as base in CH2C12 gave N-toluenesuifonyl aiiylgiycine 3.73
Chapter 3 97
TFA/CH2CI2 TsCI, pyridine,
BOCHN
20 mm, 85% CH2CI2, 80%
CO2Me TFA.HN CO2Me
OH
Ts N—...
CO2Me
3.75
Scheme 3.19: Synthesis ofepoxide 3.74 from olefin 3.63.
Different conditions were explored to favour the formation of azetidine ring 3.75 via
intramolecular nucleophilic attack and ring opening of epoxide 3.74. Attempts to prepare
azetidine ring 3.75 using AgOTf as Lewis acid with n-BuLi in THF failed. Also
employing other Lewis acid such as Cul, Cu(OTf)2, TiCI4 without base in CH2C12 only
gave starting material. Sirnilarly, only starting material was recovered after treatment of
epoxide 3.74 with KHMDS and 1 8-crown-6 ether in THF. Employing two equivalents of
either KHMDS or LiHMDS in THF led to the formation of an undesired compound
which was analyzed after purification of the crude by column chromatography by LC/MS
and ‘H NMR. According to these spectral data, p-toluenesuffinic acid was formed due to
in 80% yield after purification by column chrornatography. Epoxidation of N
toluenesulfonyl glycine 3.74 was accomplished using m-chloroperbenzoic acid (mCPBA)
in CH2CÏ2 to produce N-toluenesulfonyl glycine epoxide 3.74 in 72% yield after
purification as a mixture of two diastereomers in a 1:1 ratio (Scheme 3.19), as assessed
by measurement of the diastereomeric methyl ester singlets at 6 3.55 and 3.57 ppm in the
‘H NMR spectrum.
3.63 3.72
Is H N CO2Me
3.73
mCPBA, CH2CI2,
72% (R) +
Ts H N
(S)
3.74-(R,R) : 3.74-(R,S)
1:1
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the deprotonation of C-a in the epoxide 3.74 by LiHMDS or KHMDS followed by
cleavage ofthe N-S bond.
3.3 Conclusion
In the context of our research on general rnethods for making 4-substituted Aze
analogues, three different methodologies were pursued.
We have developed a new process for synthesizing 2,4-disubstituted azetidin-3-one 3.43
by ernploying intramolecular metal carbenoid N-H insertion of a-diazo fi
ketophosphonate 3.40 in 7 steps from L-serine. This method for the synthesis of
substituted azetidin-3-ones may be useful for the preparation of other azetidine
heterocycles.
In an investigation of the synthesis of 4-substituted Aze analogues via SN2’ approach, a
mixture of 4-propenyl N-(PhF)Aze 3.48 was synthesized by the Horner-Wadsworth
Emmons (HWE) olefination of a-tert-butyl-N-(PhF)aspartate f3-aldehyde 3.42 with /3-
keto phosphonate 3.44. Reduction of the resulting cf3-unsaturated ketone 3.45 followed
by activation of the corresponding alcohol 3.46 as the tosylate derivative 3.47 gave a
diastereomeric mixture ofpropenyl Aze 3.48 in low yield.
In an atternpt to synthesize of 4-vinyl N-(PhF) Aze 3.59 via $N2’ strategy starting from
dehydro amino adipate 3.54, the novel pipecolate 3.58 was formed instead of the 4-
substituted azetidine 3.59. One possible mechanism involves a SN2’ like nucleophilic
attack of the DMAP to the vinylic carbon of mesylate derivative 3.57 followed by
mesylate group dispiacement. Subsequent intrarnolecular N-alkylation of conesponding
intermediate via an alternative $N2’ reaction gave pipecolate 3.58.
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Also, a mixture of4-vinyl Aze analogue 3.65 was synthesized from L-Asp in 11 steps in
low yield using Ag(I) to effect the intrarnolecular SN2’ N-alkylation. 4-vinyl Aze
analogue 3.65 can serve as a precursor for the preparation of fused
azabicyclo[5.2.O]alkane arnino acid 3.13, a novel 3-turn mirnic.
Although an investigation failed to produce 4-substituted Aze by intramolecular ring
opening of an epoxide by nucleophilic attack of a j3-amine, new amino epoxides 3.70,
3.74 were synthesized for the first tirne from L-Asp as an inexpensive curai educt. These
amino epoxides may serve as interniediates for a variety of highly functionalized
compounds.
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3.4 Experimental procedure
3.4.1 General Information
Unless otherwise noted, ail reactions were run under nitrogen atmosphere and distilled
solvents were transferred by syringe. Anhydrous tetrahydrofuran (THF), dichioromethane
(DCM), acetonitrile (CH3CN) and dimethylformaide (DMF) were obtained from solvent
filtration systems. Triethylamine (Et3N) and pyridine were distilled from ninhydrin and
CaH2. Final reaction mixture solutions were dried over Na2SO4 or MgSO4 and rotary
evaporated under vacuum. Melting points are unconected. Mass spectral data,
HRMS/ESMS, were obtained by the Université de Montréal Mass Spectrometry facility.
Unless otherwise noted, ‘H NMR (300/400 MHz) and ‘3C NMR (75/100 MHz) spectra
were recorded in CDCI3. Chemical shifis are reported in ppm (6 units) downfield of
intemal tetramethylsilane ((CH3)4$i) or residual solvent (CHC13 and MeOH). Coupling
constants are reported in hertz (Hz). Chemical shifts of aromatic and vinylic carbons are
not reported for the NMR spectra of PhF containing cornpounds. Analytical thin
layer chrornatography (TLC) was performed using aluminum-backed silica plates coated
with a 0.2 mm thickness of silica gel 60 F254 (Merck KGaA Germany). Chromatography
was perforrned using Kieselgel 60 (23 0-400 mesh).
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3.4.2 Study of Carbenoid insertion into the ‘y-amino NH bond using
diazo 13-diketone and o-diazo t3-ketoester substrates
(2S)-N-Boc serine 3.25:
HQ(CO2H
NHBoc
A solution of serine 3.24 (1.05 g, 10 mmol, 100 mol%) in a mixture ofdioxane (20 mL)
and water (10 mL) was treated with a solution ofNa2CO3 (1.16 g, 11 rnrnol, 110 mol%)
in 10 mL of water, cooled in ice-water bath and treated with di-tert-butyl pyrocarbonate
(2.4 g, 11 mrnol, 110 mol%). The bath was rernoved, and stirring was continued at room
temperature for 4.5 h. The solution was concentrated in vacito to about 10-15 mL, cooled
in an ice-water bath, covered with a layer of ethyl acetate (30 mL) and acidified with a
dilute solution of KHSO4 to pH 2-3. The aqueous phase was extracted with ethyl acetate
(3 x 10 mL). The combined organic phase was washed with water (2 x 30 mL), dried
over anhydrous Na2SO4 and evaporated to give N-(Boc)-serine 3.25 as a solid (1.90 g
Yield 97%). mp 90-9 1 oc, lit. 91 °c; [a]20D -3.13 (e 2, cH3co2H), lit.27 [a]20D -3.5 + 0.5e
(e 2, CH3CO2H).
(2S)-2-tert-Butoxycarbonylamino-3-(tert-butyl-diphenyl-silanyloxy)-propionïc Acïd
3.27:
) HO1C02HPh NHBoc
A solution ofN-Boc serine 3.25 (1.5 g, 7.3 rnrnol, 100 rnol%) in 1.8 mL of DMF at room
temperature was treated with TBDPSC1 (2.4 g, 8.76 mmol, 120 mol%) and irnidazole
(1.24 g, 18.25 mmol, 250 mol%), stirred for 36 h, treated with water (20 mL) and
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extracted with ethyl acetate (3 x 100 mL), the organic layer was washed with water and
brine, dried (Na2SO4), and evaporated. The residue was purified by chromatography
eluting with 3 0-60% EtOAc in hexanes as eluent. Evaporation of the collected fractions
provided silyl ether 3.10 as a solid (3.10 g, 96 % yield). mp 150-152 oc [Œ]20 -13.4
(cl.02, CHC13) for D-serine lit,’2 mp 147-149 oc [Œ]20 +12.3e (e 0.18, CHC13) for L-
serine; ‘H NMR (CDC13, 300 MHz) 8 0.90 (s, 9H); 1.34 (s, 9 H); 3.77 (d, J 3.8 Hz,
1H); 4.01 (d, J= 9, 5 Hz, 1H); 4.32 (d, 1= 11.4 Hz, 1H); 5.30 (cl, J 11.5 Hz,
1H); 7.29-7.56 (ni, 10 H). ESMS For C24H33NO5Si (M) 443.2 HRMS calcd. For
C24H34N05 Si (M+H) 444.22008, found 444.22031.
(2S)-2-tert-Butoxycarbonylamino-3-(tert-butyl-diplienyl-sïlanyloxy)-propïonic Acid
Methyl Ester 3.38:
TBDPSO(CO2Me
NHBoc
To a suspension ofprotected amino acid 3.27 (443.Orng, immol, 100 mol%) and sodium
hydrogen carbonate (168 mg, 2mmol, 200rnol%) in dimethylformamide (DMF, 5 mL),
methyl iodide (705 mg, 5 mmol, 500 mol%) in 5 mL of DMF was added at room
temperature. The mixture was allowed to react for 24 h, then water (2 mL) was added and
the mixture was extracted with ethyl acetate (2 x 10 mL). The organic layer was washed
with water, dried with Na2SO4, evaporated to a small volume, and finally the product was
purified by colurnn chromatography using 10:90 ethyl acetate in hexanes as eluent.
Evaporation of the collected fractions provided an ou (435 mg, 91% yield) of methyl
ester 3.38: [aJ200 +15.660 (e 0.44, CHC13); ‘H NMR (CDC13, 300 MHz) 6 1.01 (s, 9H);
1.43 (s, 9 H); 3.69 (s, 3H); 3.86 (dd, J= 9.9, 7.1 Hz, 1H); 4.04 (U, J 9.9 Hz, 1H);
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4.37 (rn, 1H); 7.31-7.57 (m, 10 H). ‘3C NMR 614.2; 21.1; 29.4; 53.1; 61.9; 64.7; 74.9;
(127.9-135.6); 158.2; 179.4. HRI\4S calcd. for C25H36NO5Si (M+H) 458.23573, found
458.23586.
(3S)-[3-tert-Butoxycarbonylamino-4-Qert-butyl-diphenyl-silanyloxy)-2-oxo-butyll-
Phosphonic Acid Dimethyl Ester 3.39:
o9
‘stL P\OMe
TBDPSO OMe
NHBoc
In a 50 mL round-bottom flask equipped with a magnetic stin-ing bar and rubber septum,
under argon, a solution of dirnethyl methyl phosphonate (569.2 mg, 4.6 mmol, 500
mol%) in THF (13 mL) was placed. The mixture was cooled to -78 oc and treated by
syringe with n-BuLi (2.23 mL, 4.5 mrnol, 500 rnol% solution in cyclohexane). After 15
min the mixture was transferred to a 50 mL round bottom flask containing a -78°C
solution of methyl ester 3.38 (435 mg, 0.92 mmol, 100 mol%) in THF (16 mL). After
stining at -78°C for 2 h, the solution was quenched by addition of saturated NH4C1 (4
mL), wanned to room temperature, diluted with H20 (1.5 mL) and extracted with Et20
(10 mL) and EtOAc (2 x 10 mL). The cornbined organic phases were washed with brine
(5 mL), dried (MgSO4) and concentrated. The residue was dissolved in CHC13 (10 mL),
filtered, and concentrated to give a yeÏlow oil, that was purified by column
chrornatography over silica gel using 80-100% EtOAc in hexanes as eluant. Evaporation
ofthe collected fractions provided an oil (374 mg, 75% yield) ofbeta-keto phosphonate
3.39: [Œ]20D +35.8e (c 0.06, CHCY3); ‘H NMR (CDCI3, 300 MHz) 6 0.96 (s, 9H); 1.36
(s, 9 H); 3.67 (d, J= 10.5 Hz, 6H); 3.86 (dd, J= 10.6, 3.7 Hz, 2H); 4.02 (rn, 2H);
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4.46(m, 1H); 7.29-7.56 (ni, 10 H). ‘3C NMR 6 14.2; 19.3; 26.8; 28.4; 53.1 ; 61.9; 63.7;
79.9; (127.9-135.6); 155.2; 199.4 HRMS calcd. For C27H41NO7PSi (M+H) 550.23844,
found 550.23864.
(3S)- [3-tert-Butoxycarbonylamino-4-(tert-butyl-diphenyl-silanyloxy)-1-diazo-2-oxo-
butyl]-Phosphonic Acid Dimethyl Ester 3.40:
P-OMe
TBDPSO OMe
N2
N H B oc
In a 50 mL round bottom flask equipped with a magnetic stirring bar, under argon, NaH
(60% in minerai ou, 48.4 mg, 1.27 mmol) was washed with petroleum ether (2 x 5 mL).
After rernovai of the petroleum ether by syringe, the flask was placed under vacuum for 2
min before THF (5.3 mL) was introduced by syringe. A solution of beta-keto
phosphonate 3.39 (335 mg, 0.609 mmol) and 4-acetamidobenzenesuifonyi azide (4-
ABSA) (144.8 mg, 0.602 mmol) in 13.5 mL THF was transferred via cannula quickly at
room temperature to the round-bottom flask containing the NaH in THF. After stirring
for 1.5 h, the reaction mixture was quenched by the addition of saturated aqueous NH4C1
(2.6 mL), and extracted with Et20 (20 mL) and EtOAc (2 x 20 mL). The combined
organic phases were washed with brine (5 mL), dried and concentrated. The residue was
purified by flash colurnn chromatography over siiica gel by using 35-50% EtOAc in
hexanes as eiuent. Evaporation of the collected fractions provided a -diazo phosphonate
3.40 as an ou (240 mg, 72% yield): [Œ]20D +20.97° (c 0.12, CHCi3); IR (C11C13) Vlax (cm -
‘)2957, 2118.52 (=N2); 1715, 1661, 1269 (P=O); ‘H NMR (CDC13, 400 MHz) 6 1.03
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(s, 9H); 1.42 (s, 9 H); 3.70 (dcl, J= 25.8, 11.9 Hz, 6H); 3.87 (ni, 2H); 4.74 (rn,
1H); 5.44 ta, J = 8.3 Hz, 1H); 7.35-7.59 (m, 10 H). 13C NMR 8 19.4; 26.9; 28.5;
54.0 ; 57.66; 64.0; 80.2; (128.0-135.7); 155.3; 190.3 HRMS calcd. For C27H39N3O7PSi
(M+H) 576.22894, found 576.2284 1.
(2S)-N-(Boc)-2-(tert-Butyl-diphenyl-silanyoxymethyl)-4-(dimethoxy-phosphonyl)-3-
Azetidinone 3.41:
TB D PSO\P
BocN— ,O
P\
MeO’ OMe
In a 25mL round bottom flask equipped with a magnetic stining bar and reflux
condenser, under argon, was added a -diazo phosphonate 3.39 (70 mg, 0.12 1 mmol) and
rhodium (II) acetate dimmer (2.2 mg, 0.004 rnrnot) in CH2C12 (3.5 mL). The mixture was
stirred for 48 h at 3 5°C. The solvent was evaporated. The residue was treated with H20 (4
mL) and extracted into EtOAc (2 x 5 mL). The combined organic phase was washed with
brine (5 mL), dried, and concentrated to yellow ou 46 mg of 3.41, which was used
directly in the next step. ‘H NMR (CDC13, 400 MHz) 6 1.03 (s, 9H); 1.46 (s, 9 H); 3.75
(dcl, J= 9, 6 Hz, 3H); 3.77 (d, J= 12 Hz, 3H); 4.08 (U, J= 9 Hz, 2H); 5.21 (rn,
1H); 5.30 (rn, 2H); 7.28-7.71 (m, 10 H). ‘3C NMR 6 19.4; 26.9; 28.5; 54.0; 57.6; 64.0;
72.4; 80.2; (128.0-135.7); 155.3; 190.3. ESMS for C27H38NO7PSi (M+Na)570.0.
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(2R,4R)-2- 13-tert-Butoxycarbonyl-3-(9-phenyl-9H-flou ren-9-ylamino)-propvlideneJ
-
4-(tert-butyl-diphenyl-sïlanyloxymethyl)-3-Azetïdinone_1-Carboxylic Acid tert-Butyl
Ester 3.43:
TB D PS
Boc
COtB u
PhFHN
In a 25 mL, single neck round bottom flask equipped with a magnetic stirring bar and
rubber septum, under argon, azetidine phosphonate 3.41 (55 mg, 0.1 rnrnol, 100 mol%)
was dissolved in 3.2 mL ofTHF, cooled to 0°C, treated with aldehyde 3.42 (41.3 mg, 0.1
rnmol, lOOmol%, prepared according to reference 2$) followed by DBU (41.3mg, 0.2
mmol, 200mol%), stirred for 2.5 h and quenched by addition of sawrated aqueous NH4CÏ
(1 mL). The solution was extracted with Et20 (25 mL). The combined organic phases
were washed with brine (2 mL), dried, and concentrated. The residue was purified by
chromatography eluting with 5-10% EtOAc in hexanes as eluent. Evaporation of the
collected fractions provided cf3-unsaturated ketone 3.43 a mixture of two cis- trans
olefin isomers (according LC/MS) in a 3:1 ratio as assessed by measurement of the triplet
signals at 6 4.78 and 4.73 pprn in the ‘H NMR spectrum, as a white foam (25.9 mg, 31%
yield); [a]20D —24.T (c 0.02, CHC13); for the 1;ujor olefin isorner: ‘H NMR (CDC13, 300
MHz) 6 0.9$ (s, 9H); 1.19 (s, 9 H); 1.43 (s, 9H); 2,64-2.68 (m, 2H); 3.22-3.32 (bs,
1H); 4.12-4.19 (rn, 2H); 4.78 (t, J= 3.1 Hz, 1H); 5.58 (t, J= 5.8 Hz, 1H); 7.20-
7.65 (ni, 23H). For the major olefin isomer: ‘3C NMR ô 19.6; 26.8; 28.1; 28.5; 30.0;
33.5; 55.7; 60.1; 73.3; $1.1; 82.3; (119.9-149.4); 152.3; 174.6; 190.5.
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For the minor olefin isomer: 1H NMR (CDC13, 300 MHz) 6 1.O1(s, 9H); 1.20 (s, 9 H);
1.47 (s, 9H); 2.3 8-2.47 (m, 2H); 2.81-3.00 (bs, 1H); 3.97-4.05 (m, 2H); 4.73 (t, J=
2.3 Hz, 1H); 5.53 (t, J = 5.3 Hz, 1H); 7.20-7.65 (rn, 23H). HRMS calcd. For
C52H58N2O6Si (M+H) 835.41369, found 835.41484.
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3.4.3 Syntliesïs of 4-substituted Aze via SN2’
3.4.3.1 Synthesis of 4-propenyl Aze 3.48 from allylic alcohol 3.46 by SN2’
dispiacement (2-Oxo-propyl)-Phosphonic Acid Dîmethyl Ester 3.44:
OMe
OMe
In a 250 mL flask was placed dimethyl methyl phosphonate (6.2 g, 50 mmol, 250 rnol%)
dissolved in THF (50 mL). The mixture was cooled to -78 °C, treated with n-BuLi (20
mmol, 20 mL, 250 moÏ%, an 2.5 M solution in cyclohexane), stirred 30 min and treated
dropwise with ethyl acetate (1.762 g, 20 mmol, lOOmol%). After stirring for 3 h at -78 oc,
the reaction was quenched with 50 mL NaH2PO4, and warmed to room temperature. The
mixture was treated with brine. The phases were separated. The aqueous phase was
washed with EtOAc (5 x 50 mL), dried and evaporated. The residue was purified by
distillation (bp 76-79 °C/3mm) to give 3-keto phosphonate 3.44 (2.8 g, 82% yield); bp
78-80 ° C/3mmHg lit.29 bp 76-79 °C/3mmHg; ‘H NMR (CDC13, 400 MHz) 6 2.09 (s,
3H); 2.87 (s, 1H); 2.94 (s, 1H); 3.54(s, 3H); 3.58 (s, 3H). ESMS For C5H,204P
(M+H) 167.0.
(2S)-6-Oxo-2-(9-phenyl-9H-fluoren-9-ylamino)-hept-4-enoic Acïd tert-Butyl Ester
3.45:
I_—yCO2tBu
NHPhF
To a stirred solution of f3-keto phosphonate 3.44 (200 mg, 1.2 mmol, 100 rnol%) in
CH3CN (4.3 mL), Cs2CO3 (410.7 mg, 1.2 mL, 105 mol%) was added. The suspension
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was stirred for 30 minutes at r.t., cooled to O °C, treated with a solution of aldehyde 3.42
(497.4, 1.2 mmol, 100 mol%, prepared according to reference 2$) in CH3CN (4.3 mL),
stirred at r.t. for 3.5 h, diluted with EtOAc (15 mL) and quenched with NaH2PO4 (3 mL,
1M). The layers were separated. The aqueous layer was extracted with EtOAc (2 x 30
mL). The cornbined organic phases were washed with brine, dried and evaporated to give
a yellowish ou that was chromatographed using a gradient of 10-14% EtOAc in hexanes
to afford Œ,f3-unsaturated ketone 3.45 as an ou (366 mg, 67% yield). (aj20D —12.74e (e
0.60, CHC13); ‘H NMR (CDC13, 300 MHz) ô 1.26 (s, 9H); 2.28 (s, 3H); 2.29-2.3 8 (rn,
2H); 2.72 (t, J= 4.4 Hz, 1H); 3.31(s, 1H); 6.05 (d, J= 16 Hz, 1H); 6.72-6.80 (ni,
1H); 7.20-7.74 (ni, 13H). ‘3C NMR ô 26.8; 28.0; 39.1; 55.7; 73.1; 81.4; (120.0-149.3);
174.1; 198.5. ESMS calcd. For C3oH3iNO3Na(M+Na) 476.2. HRMS calcd. For
C30H32N03 (M+H)454.23767, found 454.23682.
(2S)-6-Hydroxy-2-(9-phenyl-9H-fluoren-9-ylamino)-hept-4-enoic Acid tert-Butyl
Ester 3.46:
NHPhF
Ketone 3.45 (100 mg, 0.22 mrnol, 100 rnol%) was dissolved in 7.0 mL of a 0.4 M
CeC13.7H20 methanol solution, cooled to -15 °C, treated slowly with NaBH4 (12.5 mg,
0.33 mmol, 150 mol%) and stirred for 2h at -15°C. The reaction was quenched with 1120
(0.5 mL), and extracted with Et20 (2 x 5 mL) and EtOAc (2 x 5 mL). The combined
organic phases were washed with brine, dried (MgSO4) and concentrated to give a
residue that was purified by column chrornatography using an eluent of 15% EtOAc in
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hexanes to ftirnish the alcohol 3.46 (82 mg, 81% yield) as a mixture oftwo diastereomers
in a 4:1 ratio (confirrned by LC/MS). ‘H NMR (CDCY3, 400 MHz) 1.17 (s, 9H); 1.27
(d, J= 4.8 Hz, 3H); 2,13 (dd, J= 13.4, 6.7 Hz, 2H); 2.60 (dd, J 12.7, 5.8 Hz,
1H); 3.1 (bs, 1H); 4.25 (dd, J= 14.2, 6.2 Hz, 1H); 5.45-5.55 (m, 1H); 5.59-5.72
(rn, 1H); 7.2 1-7.67 (rn, 13H). ‘3C NMR ô 23.44;( 23.49); 28.2; (38.84); 38.89; 56.4;
(56.5); 68.9; (69.0); 73.2; 80.9; (120.0-149.7); 174.8. (M+H) HRMS calcd. For
C30H33N03 (M+H) 456.25332, found 456.25336.
(2S)-2-(9-Ph enyl-9H-fluren-9-ylamino)-6-(toluene-4-sulfonyloxy)-hept-4-enoic Acid
tert-Butyl Ester 3.47 and N-(PhF) 3-Propyenyl Azetidine 2-tert-Butyl Ester 3.4$:
TSO
H3C FPhHN PhFN CO2tBu
3.47, 35% 3.48,11%
To a magnetically stined solution of alcohol 3.46 (188 mg, 0.41 mmol 100 mol%) in 1.3
mL of CH2CY2 and 1.7 mL of pyridine cooled at O °C was added solid p-toluene sulfonyl
chloride (237.8 mg, 1.23 mmol, 300 mol%) in one portion. The mixture was stirred at O
°C for 2h and 22 h at r.t. The mixture was evaporated and was poured into ice water, and
extracted with EtOAc (3 x 50 mL). The cornbined organic phases were washed with
brine, dried over Mg$04, filtered and concentrated. The organic solutions were
cornbined and purified by colurnn chromatography over silica gel using 3-15% EtOAc in
hexanes as eluent. Evaporation of the collected fractions gave three fractions: 57 mg of
starting material 3.46 (28%), and 21 mg ofpropenyl azetidine 3.4$ (11%) and 77 mg of
tosylate 3.47 (30%). Attempts for further purification of 3.47 and 3.4$ were unsuccessful
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and the ‘H NMR and ‘3C NMR were compiicated due to existence of two diastereomers
and two olefin isorners and showed multiple signais for some protons and carbons in
tosylate 3.47 and propenyl azetidine 3.4$.
Tosylate 3.47 was isolated as a 3:2 mixture ofdiastereomers as assessed by measurement
ofthe diastereomeric doublet signais at 6 1.45 and 1.57 pprn in the ‘H NMR spectrum.:
CDC13, 400 MHz) 6 1.15 (s, 9H); 1.45 (cl, J= 4.8 Hz, 3H); 1.49 (cl, J= 6.7 Hz, 3H);
2.06 (t, J= 6.1 Hz, 1H); 2.82-3.12 (rn, 1H); 3.18 (bs, 1H); 4.62 (t, J= 7.6 Hz, 1H);
4.81 (d,J 6.7 Hz, 1H); 5.31-5.56 (rn, 2H); 7.11-7.67 (m, 17H). ‘3CNMR6 19.1;
(19.6); 21.2; (21.9); 30.2; 35.9; 36.8; 56.7; 66.2; (66.9); 71.3; (71.7); 126.2-149.4; 174.3;
(174.8). ESMS m/z C37H49N05S (M+H) 610.2.
Azetidine 3.48 was isoiated as a 7:5 mixture of diastereomers as assessed by
measurernent of the diastereomeric triplets at 6 3.43 and 3.25 ppm in the ‘H NMR
spectrum. The ‘H NMR and ‘3C NMR in the vinylic region were complicated by olefin
isomers and two diastereomers and showed multiple signaIs for some carbons. Spectral
data for the major diastereomer: ‘H NMR (CDC13, 400 MHz) 6 1.18 (s, 9H); 1.27 (d, J
3.6 Hz, 3H); 1.97-2.10 (m, 2H); 2.51 (t, J 7.6 Hz, 1H); 2.99 (s, 1H); 3.43 (t, J= 10.9
Hz, 1H); 4.89-5.04 (2d, J= 13.2, 22.9 Hz 1H total); 5.45-5.64 (ni, 1H); 7.12-7.64 (m,
13H); for the minor isorner ‘H NMR 6 1.11 (s, 9H); 1.45 (d, J 3.6 Hz, 3H); 1.77-1.95
(m, 2H); 2.51 (t, J= 7.6 Hz, 1H); 2.99 (s, 1H); 3.24 (t, J= 10.4 Hz, 1H); 4.69-4.81 (m,
1H); 4.89-5.04 (2d, J= 13.2, 22.9 Hz 1H total); 5.3 1-5.39 (ni, 1H); 7.12-7.64 (rn, 13H);
‘3C NMR 6 17.0; 20.71;(20.78); 27.2; (27.4); 54.8; 55.1; (55.4); 72.3; 77.2; (119.0-
140.1), 173.5; 173.6. HRMS calcd. For C30H32N02 (M+H)438.4327, found 438.521$.
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4-Propyl-Azetidine-2-Carb oxylic Acid tert-Butyl Ester 3.49:
C O 2tB u
A solution of 3.48 (25 mg, 0.06 mrnol, 100 mol %) in 2 mL ofMeOH:HOAc (9:1) was
transferred into a hydrogenation apparams and treated with palladium-on-carbon (2 mg,
10 wt %). Tire pressure bottie was filled, vented, and refihled four times with $ atrn of H2.
The reaction mixture was stirred (24 h), fiitered onto a plug of Celite’ 521 (Aidrici USA),
and washed thoroughly with MeOH. The fiitrate was treated with 2 drops of iN HC1 and
the volatiles were evaporated to give a crude residue of 3.49 (10.53 mg, 93% yield) as the
hydrochloride sait which was purified by HPLC (HPLC, Prevail C1$ 5 1u, gradient 80-
10% A:0.1 TFA in H20, B: 20-90% 0.1 TFA in CH3CN; RT=12.5 mm) recovery yield
56% of Azetidine 3.49 was observed to be a 3:2 ratio of diastereorners as assessed by
measurernent of the diastereorneric multiplet signals at ô 3.51 and 3.33 ppm in tire ‘H
NMR spectrum. Spectral data for the major diastereomer: ‘H NMR (CDCI3, 400 MHz) ô
0.88-095 (ni, 3H); 1.19 (s, 9H); 1.33 (iii, 2H); 1.82 -2.00 (m, 2 H), 2.53-2.60 (ni, 1H),
3.08 (s, 1 H), 3.49-3.53 (ni, 1H); 4.74-4.90 (ni, 1H). For the minor isorner: ‘H NMR 0.88-
095 (m, 3H); 1.26 (s, 9H); 1.5$ (m, 2H); 2.10-2.23 (m, 2H), 2.53-2.60 (m, 1H), 3.0$ (s,
1H), 3.32-3.34 (m, 1H); 4.58-4.60 (m, 1H). ‘3C NMR ô 13.8; 19.8; (20.3); 28.2; 35.3;
37.1; (37.8); 48.5; (49.0); 62.9; (63.4); 84.6; (85.3); 166.6; (167.1). HRMS calcd.
200.1645 1 For C11H22N02 (M+H), found 200.16358.
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3.4.3.2 Attempted synthesis of 4-substituted Aze 3.53 from allylic alcohol 3.51 by
SN2’ reaction
(2S,7R)-7-tert-Butoxycarbonylamino-$-(tert-butyl-diphenyl-silanyloxy)-6-oxo-2-(9-
plienyl-911-fluoren-9-ylamino)-Oct-4-enoic acid tert-butyl ester 3.50:
o
Jt\ ,CO2tBu
TBDPSO
‘f
NHBoc NHPhF
To a stined solution of -keto phosphonate 3.39 (655 mg, 1.19 mrnol, 100 mol%) in
CH3CN (5 mL), Cs2CO3 (388.3 mg, 1.l9mrnol, 100 mol%) was added and the suspension
was stined for 30 min at room temperature, cooled to 0°C and treated with a solution of
aldehyde 3.42 (49 1.4 mg, 1.19 mmol, 100 mol%, prepared according to reference 28) in
CH3CN (5 mL). The mixture was stined at room temperature for 24 h, diluted with
EtOAc (60 mL), and quenched with NaH2PO4 (7.0 mL, 1M). The layers were separated,
and the aqueous layer was extracted with EtOAc (2 x 2OmL). The combined organic
layers were washed with brine, dried, and evaporated to give yellowish oil that was
chromatographed using a gradient of 3-6% EtOAc in hexanes to afford 3.50 as clear ou
(710 mg and 72% yield). [a]200 30.850 (c 0.02, CHC13); ‘H NMR (CDC13, 300 MHz)
1.03 (s, 9H); 1.21 (s, 9 H); 1.48 (s, 9H); 2.12-2.31 (m, 2H); 2.68 (t, J = 5.7 Hz,
1H); 3.31 (s, 1H); 3.95-4.01 (rn, 2H); 4.58-4.69 (dd, J= 7.0, 3.3 Hz 1H); 5.62-5.72
(t, J = 7.7 Hz, 1H); 6.2 (cl, J = 15.8 Hz, 1H), 6.79-7.04 (rn,YH); 7.20-7.72 (rn,
23H). ‘3C NMR 19.6; 27.1; 28.2; 28.7; 39.3; 55.9; 59.8; 64.6; 73.3; 79.9; 81.6; (120.1-
149.4); 155.6; 174.3; 196.0. HRMS calcd. For C52H6,N2O6Si (M+H) 837.42934, found
837.43226.
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(2S,7R)-7-tert-Butoxycarbonylamino-8-(tert-butyl-diphenyl-silanyloxy)-6-hydroxy-
2-(9-phenyl-9H-fluoren-9-ylamino)-Oct-4-enoic Acid tert -Butyl Ester 3.51:
OH
,CO2tBu
TBDPSO ‘j’
NHBoc NHPhF
a,f3-Unsaturated ketone 3.50 (335 mg, 0.4 mmol, 100 mol%) was dissolved in 20 mL ofa
solution of 0.4 M CeCI3.7H20 in methanol, cooled to -15 °C, treated slowly with NaBH4
(22.7 mg, 0.6 mmol, 150 mol%), stined for 2h at -15 °C, and quenched with H20 (1 mL).
The mixture was extracted with Et20 (2 x 10 mL) and EtOAc (2 x 10 mL). The combined
organic phases were washed with brine, dried (MgSO4) and concentrated to give a
residue that was purified by colurnn chrornatography using an eluent of 10-15% EtOAc
in hexanes to furnish alcohol 3.51 (263 mg, 78% yield) as a pure diastereomer (E-olefin
isomer) (confirrned by LC/MS and ‘H NMR) as a white foam; [a]20D —65.8° (e 0.01,
CHCY3); ‘H NMR (CDCI3, 400 MHz) ô 1.11 (s, 9H); 1.22 (s, 9 H); 1.44(s, 9H); 2.12
(dd, J= 13.6, 6.5, Hz, 2H); 2.64 (dd, J 11.6, 5.8 Hz , 1H); 3.2 (bs, 1H); 3.71-
3.77 (ni, 2H); 3.83 (d, J= 4.1 Hz, 1H); 3.92 (dd, J= 10.3, 3.6 Hz, 1H); 4.30 (d, J
= 4.8 Hz , 1H); 5.2 (d, J= 8.1 Hz, 1H); 5.5 (dd, J= 15.4, 5.8 Hz, 1H), 5.77-5.87
(ni, 1H); 7.20-7.71 (m, 23H). ‘3c NMR ô 14.1; 19.1; 26.7; 27.8; 28.2; 55.0; 55.9; 63.8;
72.9; 73.6; 79.2; 80.5; (119.5-149.3); 157.2; 174.4. HRMS calcd. For c52H63N2o6si
(M+H) 839.44499, found 839.44499.
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3.4.3.3 Attempteil synthesis of4-vinyl Aze 3.59 from allylic alcohol 3.55
(2S)-6-Hydroxy-[N-(PhF)arninoJ-hex-4-enoic Acid tert-Butyl Ester 3.55:
OH
PhFHN CO2tBu
b a stirred solution of diester 3.54 (1g, 2.01 rnrnol, 100 mol%, prepared according to
reference 16) in THF (40.5 mL) at -40 °C, DIBAL-il (1 M solution in toluene, 8.06
mrnol, 400 mol%) was added. The mixture was stirred for 1.5 h, quenched with acetone
(1.5 mL) diluted with MeOH (8 mL), and allowed to warm to room temperature and
evaporated. The residue was dissolved in ether (50 mL) and extracted with 1 M NaOH (3
x 30 mL), washed with brine, dried (MgSO4), and evaporated. The residue was purified
by column chromatography using 20% EtOAc in liexanes as eluent to yield 893 mg of
3.55 as ou (95% yield). [Œ]20 —248.51° (c 1.0, cHct3); ‘H NMR (cDcl3, 400 MHz)
1.28 (s, 9H); 2.26 (t, J= 6.02 Hz, 2H); 2.42 (t, J= 7.21 Hz, 1H); 2.71-2.74(rn,
1H); 4.12 (d, J= 4.24 Hz, 2H); 5.68-5.72 (rn, 2H); 7.26-7.75 (rn, 13H). 13C NMR c5
28.0; 38.0; 76.1; 56.2; 63.4; 73.2; 80.8; (119.8-149.6); 174. HRMS calcd 442.2378 For
C28H31N03 (M+H) 442.2376.
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6-Methansu lfonyloxy-N-Phf-hex-4-enoic Acid tert-Butyl Ester 3.57 and N(PhF)
1 ,2,3,4-tetrahydro-Pvrïdine-2-Carboxylic Acid tert-Butyl Ester 3.58:
OMs
CO2tBu
PhFHN CO2tBu PhF
To an ice-cooled solution of alcohol 3.55 (589 mg, 1.33 mmol, 100 rnol%),
triethylamine (405.2 mg, 4.00 rnmol, 300 mol%), DMAP (16.2 mg, 0.133 rnrnol, 10
mol%) in dichiorornethane, methanesulfonyl chloride (304.5 mg, 2.66 rnrnol, 200 mol%)
was added. The bath was removed and the mixture was allowed to warrn to r.t. After
24h, the reaction mixture was diluted with water (15 mL) and extracted twice with
EtOAc. The organic layers were washed with brine, dried and evaporated to a residue,
that was chromatographed with 3-10% EtOAc in hexanes as eluent to give 297 mg of
mesylate 3.57 (43% yieÏd) and 214 mg ofpipecolate 3.58 (38% yield).
Mesylate 3.57: 1H NMR (CDCY3, 400 MHz) 6 1.10 (s, 9H); 2.0$ (t, J= 5.7 Hz, 2H);
2.51 (t, J = 8.08 Hz, 1H); 2.8$ (s, 3H); 3.08-3.18 (bs, 1H); 4.57 (d, J = 8.8 Hz,
2H); 5.45-5.51 (rn, 1H); 5.70-5.85 (m, 1H); 7.11-7.58 (ni, 13H). ‘3C NMR 628.0;
38.0; 76.1; 56.2; 63.4; 73.2; 80.8; (1 19.8-149.6); 174.8; ESMS m/z for C30H33N05S (M+)
5 19.9.
Pipecolate 3.58: [a]20D —109.51° (c 0.06, CHC13); ‘H NMR (CDC13, 400 MHz) 6 1.11 (s,
9H); 2.07 (dd, J= 12.5, 6.2 Hz, 2H); 2.51 (t, J= 6.09 Hz, 1H); 3.92 (d, J= 6.8 Hz,
2H); 5.46-5.53 (m, 1H); 5.59-5.65 (rn, 1H); 7.10-7.58 (rn, 13H). ‘3C NMR 6 28.1;
3$.7;45.4; 56.1; 73.2; 8 1.1; (120.0-149.6); 174.5. HRMS calcd. For C29H30N02 (M+H)
424.2271, found 424.22537.
Chapter 3 117
3.4.3.4 Synthesïs of 4-vinyl Aze 3.65 via SN2’ reaction of alylic chloride 3.64
(2S)2-tert-Butoxycarhonylamino-pent-4-enoic Acïd Methyl Ester 3.63:
BocHN 2 e
To a suspension of N-(Boc)allylglycine 3.62 (340mg, 1.58 rnrnol,lOOmol% prepared
according to reference 28, 20) and sodium hydrogen carbonate (265.5 mg, 3.16 mmol,
200mol%) in dimethylformamide (5 mL), methyl iodide (1.11 g, 7.9 rnrnol, 500 mol% in
5 ml DMF) was added at room temperature. The mixture was stirred for 24 h, treated
with water (20 mL) and extracted with ethyl acetate (4 x 10 mL). The organic layer was
washed with water, dried with Na2SO4, evaporated to a small volume that was purified by
colurnn chrornatography using 10% ethyl acetate in hexanes as eluent. Evaporation of the
collected fractions provided ester 3.63 as an ou (315 mg, 87 % yield). [Œ20D +15.75° (e
0.02, CHCÏ3); 1H NMR (CDC13, 400 MHz) 6 1.33 (s, 9H); 2.39 (ni, 2H); 3.61 (s,
3H); 4.27 (dd, J= 13.7, 6.2 Hz, 1H); 5.04 (m, 3H); 5.57 (m, 1H). ‘3CNMR ô 28.4;
36.7; 53.0; 54.5; 80.5; 119.5; 132.4; 155.8; 176.4. ESMS For C11H20N04 (M+H)230.1
HRMS calcd. For C11H19NO4Na (M+Na) 252.1206, found 252.1205.
(2S)-2-tert-Butoxycarbonylamino-6-chloro-hex-4-enoic Methyl Ester 3.64:
CI
BocHN CO2Me
To a solution ofN-(Boc)allylglycine methyl ester 3.63 (230 mg, 1.003 mrnol, 100 mol%)
and allyl chloride (307.2 mg, 4.015 mmol, 400 mol%) in CH2C12 (17 mL), Grubbs second
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generation catalyst benzyl idene[ 1,3 -bis(2 ,4,6-trirnethylphenyl)-2-
irnidazolidinylidene] dichloro(tricyclohexylphosphine)ruthenium (87.6 mg, 0.1 rnmol, 10
rnol%) was added. The mixture was heated at reflux for 17 h. The solvents were
evaporated under reduced pressure. The residue was chromatographed on silica gel using
of 3-10% EtOAc in hexanes as eluent afforded 3.65 (172 mg, 62%) as a clear ou. [a200
+33.73 (c 0.01, CHCI3). ‘H NMR (CDCI3, 400 MHz) ô 1.40 (s, 9 H); 2.40-2.47 (rn, 1H);
2.52-2.58 (rn, 1H); 3.72 (s, 3H); 3.9$ (dd, J= 19.2, 8.2 Hz, 2H); 4.35 (dd, J= 13.2, 6.1
Hz, 1H); 5.07 (J= 7.7 Hz, 1H); 5.60-5.72 (rn, 2H). ‘3C NMR (CDC13, 400 MHz) ô 27.5;
34.5; 43.7; 51.6; 52.1; 79.3; 128.3; 129.5; 154.3; 171.5. HRMS calcd. For
C,2H20C1NO4Na (M+Na) 300.0973, found 300.0985.
N-(Boc)-4-Vinyl Azetidine 2-Methyl Ester 3.65:
CO2M e
Under argon, a]lyl chloride methyl ester 3.64 (50 mg, 0.1$ mmol, 100 mol %) was
dissolved in THF (0.7 mL), cooled to -7$ °C, treated dropwise with a solution of n-BuLi
(0.07 mL, in cyclohexane, 2.5 M), stirred at -7$ °C for 15 mm, treated with silver triflate
(74.2 mg, 0.28 mrnol, 160 mol%) and the resulting light brown solution was allowed to
wann to r.t. over 1.5h and stin-ed for an additional 1h. The resulting heterogeneous
reaction mixture was diluted with ether, washed successively with 2N HC1, samrated
NaHCO3, and brine, dried (MgSO4), and concentrated under reduced pressure to a
residue that was clwornatographed using 10-25% EtOAc in hexanes as eluant to provide
vinyl azetidine 3.65 (12 mg, 25% yield) as a colorless ou; The ‘H NMR and ‘3C NMR
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were complicated by carbamate cis and trans-isorners and diastereomers of N-Boc 4-
vinyl azetidine 2-methyl ester 3.65 and showed multiple signal for sorne carbons: ‘H
NMR (CDC13, 500 MHz, at 25 °C) in the vinylic region exhibited two trans and two cis in
a 5.7:1 ratio as assessed by measurement of the cis doublet signais at ô 5.38 and 5.1$
ppm. 6 1.50 (s, 9 H); 1.61-1.70 (rn, 1H); 1.87-2.05 (rn, 1H); 3.75 (s, 3H); 4.39-4.58 (m,
1H); 5.10 (bs, 1H); 5.20 and 5.35 (2d, J 5.8, 8.2 Hz, total 1H); 5.33 and 5.48 (2d, J
14.2 , 18.3 Hz, total 1H); 5.78-5.91 (ni, 1H). ‘H NMR (CDCI3, 500 MHz at -55 °C) 6 in
the vinylic region exhibited two trans and two cis in a 2.7:1 ratio as assessed by
measurement of the cis doublet signals at the same chernical shift as described above. ô
1.49 (s, 9 H); 1.60-1.71 (in, 1H); 1.90-2.15 (m, 1H); 3.81 (s, 3H); 4.52-4.61 (m, 0.5H);
4.83-4.92 (m, 0.5H); 5.1$ (d, J 14.3 Hz, 1H); 5.20 (2d, J 6.2, 6.5 Hz, total 1H);
5.35, 5.50 (2d, J= 15.2, 17.8 Hz, total 1H); 5.83-5.92 (in, 1H). ‘3C NMR (CDCI3, 500
MHz at -55 °C) 6 28.3; 36.9; 41.3; 50.2; 5 1.2; 52.2; 53.5; 68.0; 78.5; 78.5; 81.0; 81.3;
115.2; 120.7; 134.0; 134.2; 138.7; 155.4; 157.0; 173.5; 175.6. ‘3C NMR (CDC13, 500
MHz at 25 °C) 28.5; 35.0; 37.4; 41.4; 51.0; 51.7; 52.9; 68.6; 78.4; 80.9; 114.9; 119.4;
134.7; 139.8; 156.9; 173.4. HRMS calcd. For C,2H20N04 (M+H) 242.10038, found
242.10159.
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3.4.4 Attempted syntliesïs of 4-substituted Aze via intramolecular nucleophilic ring
opening of an epoxide:
(2S)-2-tert-Butoxycarbonylamino-3-oxiranyl-Propionic Acid Methyl Ester 3.70:
o
BocHN CO2Me
To a stirred solution of N-Boc allylglycine 3.63 (IOOmg, 0.436 mmol, 100 mol%,
prepared according to reference 19) in CH2CI2 was added rn-chloroperbenzoic acid (m
CPBA, 370 mg, 2.13 rnrnol, 490 rnol%). After 5 h, the mixture was filtered through a
glass fiher, the solids were washed with CH2C12, and the combined organic filtrate and
washings were cooled to O °C and washed with Na2SO3 (2 mL). The mixture was filtered
and organic phase was washed with 10% Na2SO3, 10% NaHCO and water. After drying
(MgSO4), filtration and evaporation of the volatiles, the residue was chromatographed on
silica gel using a gradient of 20:80 EtOAc in hexanes to afford a mixture of two
diastereorners of epoxide 3.70 in a 4:1 ratio (according to LC/MS) as clear ou (70 mg,
70% yields). 1H NMR (CDCI3, 300 MHz) ô 1.29 (s, 9H); 1.60-1.75 (m, 1H); 1.88-2.11
(rn, 1H); 2.33 (dd, J= 4.8, 26 Hz, 1H); 2.62 (dd, J= 7.2, 3.9 Hz, 1H); 2.84-2.87 (m, 1H);
3.60 (s, 3H); 4.29 (t, J= 6.9 Hz, 1H); 5.17 (s, 1H); ‘3C NMR ô 28.6; 35.7; (35.9); 46.8;
(47.0); 49.4; 52.1; 52.8; 76.9; 155.5; (155.9); 172.8. HRMS calcd. For C11H70N05
(M+H)246.1342, found 246.1342.
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(2S)-2-(Toluene-4-sulfonylamino)-pent-4-enoic Acid Methyl Ester 3.73:
TsHN CO2Me
To a solution of allylglycine methyl ester hydrochioride 3.72 (20 mg, 0.119 rnrnol, 100
mol %, prepared according to reference 6) in CH2C12 (1.4 mL), pyridine (18.8 mg, 0.238
rnrnol, 200 rnol%) followed by p-toluene sulfonyl chloride (23 mg, 0.119 mmol, 100
rnol%) were added. The mixture was stirred for 36 h at room temperature, and then
waslied with brine and water. After drying (MgS04) and concentration of the volatiles,
the residue was chromatographed on silica gel using a gradient of 15-20% EtOAc in
hexanes to give sulfonamide 3.73 as an ou (27 mg, 80% yield) [aj20D +11.12 (c 0.04,
CHCI3). 1H NMR (CDC13, 400 MHz) 8 2.41 (s, 3H); 2.45 (t, J= 6.6 Hz, 2H); 3.51 (s,
3H); 4.01-4.04 (m, 1H); 5.05-5.10 (m, 2H); 5.22 (d, 1= 8.9 Hz, 1H); 5.58-5.62 (m,ÏH);
7.26-7.72 (m, 4H). ‘3C NMR (CDCI3, 400 MHz) 6 21.8; 37.8; 52.7; 55.5;120.0; 127.5;
129.9; 131.5; 137.0; 144.0; 171.6. ESMS mlz 284.0 For C13H17N04$ (M+H). HRMS
calcd. For C13H17N04S (M+H) 284.09511, found 284.09570.
(2)-3-Oxirany1-2-(to1uene-4-su1fonyIamino)-Propionic Acïd Methyl Ester 3.74:
o
TsHN CO2Me
Epoxide 3.74 was synthesized according to the procedure described for the synthesis of
Chapter3 122
epoxide 3.70 above using N-toluenesulfonyl allyglycine methyl ester 3.73 (50 mg, 0.176
mmol, 100 mol %) in CH2Cb (2 mL) and m-chloroperbenzoic acid (m-CPBA, 370 mg,
2.13 rnrnol, 500 mol%). The residue was purified on silica gel using a gradient of 20-
35% EtOAc in hexanes afforded a mixture 1:1 of two diastereomers in a ratio 1:1 as
assessed by measurernent of the diastereomeric methyl ester singlet at ô 3.52 and 3.56
pprn in the LH NMR spectrum 3.74 as white solid (38 mg, 72% yields). 1H NMR (CDCY3,
400 MHz) ô 1.81-2.10 (rn, 2H); 2.41 (s, 3H); 2.49 (t, J= 5.3 Hz, 1H); 2.73-2.77 (m, 1H);
2.92-3.02 (ni, 1H); 3.52 (s, 3H); 4.12 (t, J= 6.2 Hz, 1H); 5.52 (d, J 7.8 Hz, 1H); 7.26-
7.74 (m, 4H). 13C NMR ô 21.8; 36.4; 36.8; 47.1; 47.3; 48.6; 49.1; 49.0; 53.0; 53.1; 53.8;
54.1; 127.5; 129.9; 130.0; 136.6; 136.8; 144.1; 171.6; 171.8. HRMS calcd. for
C13H18N05 S (M+H)300.0900, found 300.0908.
Chapter3 123
3.5 References:
1) Cluzeau, J.; Lubeli, W. D. Biopotymers (Feptide Science) 2005, 80, 98.
2) Halab, L.; Gosselin, F.; Lubeli, W. D. BiopoÏymers (Peptide Science) 2000, 55, 101.
3) ‘The chernistry of6-lactarn’ Ed. M.I. page, Blackie Academic & Professional, London,
1992, 233-285.
4) Baldwin, R. M.; Adlington, R. H.; Jones, R. H.; Schofield C.; Zaracostas, C.
Tetrahedron 1986, 42, 4879.
5) Polech, J.; Seebach, D. Helv. Chini. Acta 1995, 78, 1238.
6) Moyer, M. P.; Feidman, P. L.; Rapoport, H. iOrg. Chein. 1985, 50, 5223.
7) Frigola, J.; Tonens, A.; Castrillo, J. A.; Salgado, J.; Quintana, J. R. I lied. Chein.
1994, 57,4 195.
8) Axenrod, T.; Watnick, C.; Yazdikhasti, H. I Org. Chem. 1995, 60, 1959.
9) Hanessian, S.; Fu, J.; Chiara, J. L.; Di Fabio, R. Tetrahedron Lett. 1993, 34, 4157.
10) Eustache, J.; Van de Weghe, P.; Le Nouen, D.; Uyehara, H.; Kabuto, C.; Yamamoto,
Y. J. Org. Chem. 2005, 70, 4043.
11) Doyle, M. P.; McKervey, M.A.; Ye, T. Modem Catatytic Methods for Organic
Synthesis with Diazo Compottnds: from CycÏopropanes to Ylides; John Wiley and Sons:
NewYork, 1998.
12) Emmer, G. Tetrahedron 1992, 48, 7165.
13) Hanessian, S.; Fu, J. Can. I Chem. 2001, 1812.
14) Burtoloso, Antonio C. B.; Correia, Carlos, R. D. Tetrahedron Lett. 2004, 45, 3355.
15) Davis, F., A.; Wu, Y.; Xu, H.; Zhang, J. Org. Lett. 2004, 6, 4523.
16) Gosselin, F.; Lubeli, W. D. I Org. Chein. 1998, 63, 7463.
Chapter 3 124
17) Takao, K. I.; Nigawara, Y,; Nishino, E.; Takagi, I.; Koji, M.; Tadano, K. I.; Ogawa,
S. Tetrahedron 1994, 50, 5681.
18) Hirai, Y.; Watanabe, J.; Nozaki, T.; Yokoyarna, H. Yamaguchi, S. I Org. Chem.
1997, 62, 776.
19) Yokota, W.; Shindo, M.; Shishido, K. HeterocycÏes 2001, 54, 871.
20) Kaul, K.; Surprenant, S.; Lubeli, W. D. I Org. Chem. 2005, 70, 3838.
21)Swarbrick, M. E.; Gosselin, F.; Lubeli, W. D. 1 Org. Chem. 1999, 64, 1993.
22) Kaul, R.; Brouillette, Y.; Sajjadi, Z.; Hansford, K. A.; Lubeil, W.D. I Org. Chem.
2004, 69, 6131.
23) Toda,T. Karikorni, M.; Oshima, M.; Yoshida, M.; HeterocycÏes, 1992, 33, 511.
24) Karikomi, M.; Arai, K.; Toda, T. Tetrahedron Lett. 1997, 38, 6059.
25) Christe, B. D.; Rapoport, H. 1 Org. Chem. 1985, 50, 1239.
26) For review see: a) Lohray, B. B. Synthesis 1992, 1035. b) Kolb, H. C.; Van
Nieuwenhze, M. S.; Sharpless, K. B. Chem. Rev. 1994, 94, 2483.
27) Sigrna-Aldrich 2006 catalog, page 409.
28) Swarbrick, M. E.; Gosselin, F.; Lubeli, W. D. I Org. Chem. 1999, 64, 1993.
29) Sigrna-Aldrich 2006 catalog, page 1011.
Chapter4 125
CHAPTER 4
Conclusions and Perspectives
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4.1 Conclusion, future work and perspectives:
Incorporation of conforrnational constraints, such as a proline or proline homologue, into
a biologically active peptide can enhance receptor selectivity and modulate ligand
efficacy. With this aim we have developed methodologies for the synthesis of 3- and 4-
substituted azetidine-2-carboxylic acids to serve as tools for studying the conformational
requirements ofbiologically active peptides.
In Chapter 2, enantiopure 3-substituted azetidine-2-carboxylic acids containing different
heteroatomic side chains were synthesized from L-Asp as chiral educt. 3-Substituted Aze
analogues were prepared to serve as azetidine amino acid chirneras of Lys, nor-leucine
and arninoadipate. In light of the activity of 3-carboxymethyl Aze (t-CAA) 1.3 6, a Glu
Aze chimera, to inhibit excitatory arnino acid transporters, the potential for arninoadipate
Aze 2.4 to exhibit activity merits investigation and may now be explored, because of our
efficient synthesis.
In Chapter 3, prelirninary experiments were made to prepare 2,4-disubstituted azetidines.
For example, 4-substituted azetidine 2-phosphonate 3.41 was synthesized starting from
L-serine 3.3$ by a route featuring an intramolecular diazo insertion reaction of Œ-diazo 3-
ketophosphonate 3.40. This Aze analogue may be considered as a mimic of the
conesponding a-aminocarboxylic acid and was used in Wittig chemistry to provide 2,4-
disubstituted azetidine-3-one 3.43. A potential application of 2,4-disubstituted azetidine
3-one 3.43 as an intermediate for the synthesis of target azabicyclo[4.2.O]alkane amino
acid 3.12 is illustrated in $cheme 4.1.
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NHPhF O ,OR
PHNCO2H
PHN
°CO2tBu
DTBDPS OTBDPS OTBDPS
3.12, p protecting group 4.1 4.43 341
Scheme 4.1: Retro synthesis of target azabicyclo[4.2.O]alkane amino acid 3.12 from
azetidine phosphonate 3.41.
Another investigation to synthesize 4-substituted Aze analogues via SN2’ reaction, bas
produced 4-propenyl Aze analogue 3.48 as a diastereorneric mixture. Moreover, a nove!
pipecolate 3.58 was prepared as an interesting alternative product to 4-vinyl N-(PhF)Aze
3.59 when DMAP was used in the SN2’ reaction. 4-vinyl Aze 3.65 was synthesized using
Ag(I) to effect the intramolecular SN2’ N-alkylation of 3.64. 4-Vinyl Aze 3.65 may serve
as precursor for the preparation of fused azabicyclo[5.2.O]alkane amino acid 3.13, a novel
t3-turn mirnic (Scheme 4.2).
BOCHN002Me
CO2Me CO2Me CO2Me
BocHN
3.13 4.3 4.2 3.65
Scheme 4.2: Retro synthesis of target azabicyclo[5,2,O]alkane 3.13 from vinyl azetidine
3.65.
In this route, the key step would be N-acylation of 4-vinyl Aze 3.65 to provide dipeptide
4.3 for ring-closing metathesis and construction of fl-lactam 3.13.
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Although an investigation failed to produce 4-substituted Aze by intrarnolecular ring
opening of an epoxide by nucleophilic attack of a f3-amine, new amino epoxides 3.70,
3.74 were synthesized for the first time from L-Asp. These novel arnino epoxides could
be considered as intermediates for synthesis of functionalized compounds such as amino
alcohols.5
This research has thus touched on the field of peptide mimicry by providing new
rnethodology and design for the synthesis of conformationally constrained compounds
that may induce mm motifs when introduced into peptides and proteins. The important
roles turns play in peptide recognition and biological activity suggest that the 3- and 4-
substituted Aze analogues have interesting potential for studying conformation-activity
relationships effecting potency, metabolic stability, and activity of biologically active
peptides in medicinal chernistry and peptide science. Approaches for synthesizing 4-
substituted azetidinone 3.43 and 4-substituted Aze analogues 3.48 and 3.65 offer
potential for the construction of azabicyclo[X.2.O]alkane amino acids such as 3.12 and
3.13. Future work on the synthesis of ffised ring systems such as 3.12 and 3.13 will
require improved methods for 4-substituted Aze synthesis. In this light, the described
methods for making 3- and 4-substituted Aze analogues provides a solid foundation for
the research activity of future colleagues.
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Appendix 2
1J] NMR and ‘3C NMR and HRMS of compounds related to
chapter 3
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